MXPA94005931A - Compositions of oil emulsion in water for personal cleaning - Google Patents
Compositions of oil emulsion in water for personal cleaningInfo
- Publication number
- MXPA94005931A MXPA94005931A MXPA/A/1994/005931A MX9405931A MXPA94005931A MX PA94005931 A MXPA94005931 A MX PA94005931A MX 9405931 A MX9405931 A MX 9405931A MX PA94005931 A MXPA94005931 A MX PA94005931A
- Authority
- MX
- Mexico
- Prior art keywords
- ppg
- ether
- composition according
- emulsion composition
- group
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 176
- 239000000839 emulsion Substances 0.000 title claims description 96
- 238000004140 cleaning Methods 0.000 title claims description 56
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims description 43
- 210000003491 Skin Anatomy 0.000 claims abstract description 104
- 239000004480 active ingredient Substances 0.000 claims abstract description 71
- 238000000151 deposition Methods 0.000 claims abstract description 14
- 239000007764 o/w emulsion Substances 0.000 claims abstract description 12
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical group OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims abstract 2
- 229960001860 salicylate Drugs 0.000 claims abstract 2
- 229920000642 polymer Polymers 0.000 claims description 109
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 104
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 71
- -1 eptromicin Chemical compound 0.000 claims description 70
- DUFKCOQISQKSAV-UHFFFAOYSA-N 2-(2-hydroxypropoxy)propan-1-ol Chemical compound CC(O)COC(C)CO DUFKCOQISQKSAV-UHFFFAOYSA-N 0.000 claims description 54
- 125000000217 alkyl group Chemical group 0.000 claims description 41
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 40
- 229960004889 salicylic acid Drugs 0.000 claims description 35
- 125000002091 cationic group Chemical group 0.000 claims description 34
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 34
- CUVLMZNMSPJDON-UHFFFAOYSA-N 1-(1-butoxypropan-2-yloxy)propan-2-ol Chemical compound CCCCOCC(C)OCC(C)O CUVLMZNMSPJDON-UHFFFAOYSA-N 0.000 claims description 33
- 239000002253 acid Substances 0.000 claims description 31
- 229920001451 Polypropylene glycol Polymers 0.000 claims description 28
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 28
- 239000003995 emulsifying agent Substances 0.000 claims description 26
- 229920002678 cellulose Polymers 0.000 claims description 24
- 239000001913 cellulose Substances 0.000 claims description 21
- 239000003431 cross linking reagent Substances 0.000 claims description 21
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 21
- 239000000178 monomer Substances 0.000 claims description 20
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 18
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- 239000003921 oil Substances 0.000 claims description 16
- 239000002562 thickening agent Substances 0.000 claims description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 15
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 claims description 14
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 14
- 239000004202 carbamide Substances 0.000 claims description 14
- JOYRKODLDBILNP-UHFFFAOYSA-N ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims description 14
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 14
- 150000002170 ethers Chemical class 0.000 claims description 13
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims description 13
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 12
- GHMLBKRAJCXXBS-UHFFFAOYSA-N Resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 claims description 12
- 150000002191 fatty alcohols Chemical class 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 11
- 239000011780 sodium chloride Substances 0.000 claims description 11
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 claims description 10
- BXWNKGSJHAJOGX-UHFFFAOYSA-N Cetyl alcohol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 10
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 10
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 10
- 229960000541 cetyl alcohol Drugs 0.000 claims description 10
- 229960001680 ibuprofen Drugs 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 10
- IBLKWZIFZMJLFL-UHFFFAOYSA-N 1-phenoxypropan-2-ol Chemical compound CC(O)COC1=CC=CC=C1 IBLKWZIFZMJLFL-UHFFFAOYSA-N 0.000 claims description 9
- 229940106026 PHENOXYISOPROPANOL Drugs 0.000 claims description 9
- GLDOVTGHNKAZLK-UHFFFAOYSA-N Stearyl alcohol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 9
- 125000005466 alkylenyl group Chemical group 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- DXGLGDHPHMLXJC-UHFFFAOYSA-N Oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 claims description 8
- HRPVXLWXLXDGHG-UHFFFAOYSA-N acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 8
- PUPZLCDOIYMWBV-UHFFFAOYSA-N butylene glycol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 229960001173 oxybenzone Drugs 0.000 claims description 8
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 7
- YDCSFYSJEYSCBP-UHFFFAOYSA-N 3-hexadecoxypropan-1-ol Chemical compound CCCCCCCCCCCCCCCCOCCCO YDCSFYSJEYSCBP-UHFFFAOYSA-N 0.000 claims description 7
- 229960001727 Tretinoin Drugs 0.000 claims description 7
- 229940051250 hexylene glycol Drugs 0.000 claims description 7
- 239000003906 humectant Substances 0.000 claims description 7
- OAAZUWWNSYWWHG-UHFFFAOYSA-N 1-phenoxypropan-1-ol Chemical compound CCC(O)OC1=CC=CC=C1 OAAZUWWNSYWWHG-UHFFFAOYSA-N 0.000 claims description 6
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-Methyl-2,4-pentanediol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 claims description 6
- BDJRBEYXGGNYIS-UHFFFAOYSA-N Azelaic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 claims description 6
- 229960003921 Octisalate Drugs 0.000 claims description 6
- 229960005323 Phenoxyethanol Drugs 0.000 claims description 6
- QCDWFXQBSFUVSP-UHFFFAOYSA-N Phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 6
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 claims description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 6
- 239000003974 emollient agent Substances 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- WCJLCOAEJIHPCW-UHFFFAOYSA-N octyl 2-hydroxybenzoate Chemical compound CCCCCCCCOC(=O)C1=CC=CC=C1O WCJLCOAEJIHPCW-UHFFFAOYSA-N 0.000 claims description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-M stearate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 claims description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 claims description 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 5
- GPLRAVKSCUXZTP-UHFFFAOYSA-N 3-(2,3-dihydroxypropoxy)propane-1,2-diol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 claims description 5
- JYGXADMDTFJGBT-VWUMJDOOSA-N Cortisol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 5
- CMWTZPSULFXXJA-VIFPVBQESA-N Naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 5
- FMJSMJQBSVNSBF-UHFFFAOYSA-N Octocrylene Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 claims description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- AEMRFAOFKBGASW-UHFFFAOYSA-M glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 claims description 5
- 229960000890 hydrocortisone Drugs 0.000 claims description 5
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 5
- 229960002009 naproxen Drugs 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 229960000601 octocrylene Drugs 0.000 claims description 5
- 239000010452 phosphate Substances 0.000 claims description 5
- 229920002401 polyacrylamide Polymers 0.000 claims description 5
- 229960001755 resorcinol Drugs 0.000 claims description 5
- RHEFZZHALQVVFD-KTKRTIGZSA-N 3-[(Z)-octadec-9-enoxy]propan-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCO RHEFZZHALQVVFD-KTKRTIGZSA-N 0.000 claims description 4
- AFDXODALSZRGIH-QPJJXVBHSA-N 4-Methoxycinnamic acid Chemical compound COC1=CC=C(\C=C\C(O)=O)C=C1 AFDXODALSZRGIH-QPJJXVBHSA-N 0.000 claims description 4
- USIUVYZYUHIAEV-UHFFFAOYSA-N Diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 claims description 4
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 4
- 150000001450 anions Chemical group 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 230000002596 correlated Effects 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 claims description 4
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- SZXQTJUDPRGNJN-UHFFFAOYSA-N Dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims description 3
- 229940023565 PPG-10 Cetyl Ether Drugs 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000004429 atoms Chemical group 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 125000005356 cycloalkylalkenyl group Chemical group 0.000 claims description 3
- OTMSDBZUPAUEDD-UHFFFAOYSA-N ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 claims description 3
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 claims description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 3
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 claims description 2
- LCZVSXRMYJUNFX-UHFFFAOYSA-N 2-[2-(2-hydroxypropoxy)propoxy]propan-1-ol Chemical compound CC(O)COC(C)COC(C)CO LCZVSXRMYJUNFX-UHFFFAOYSA-N 0.000 claims description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N Docosanol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 claims description 2
- LQZZUXJYWNFBMV-UHFFFAOYSA-N Dodecanol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 claims description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N Oleyl alcohol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 claims description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 2
- 229960003920 cocaine Drugs 0.000 claims description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 2
- ZPUCINDJVBIVPJ-BARDWOONSA-N cocaine Natural products O([C@@H]1C[C@H]2CC[C@H](N2C)[C@@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-BARDWOONSA-N 0.000 claims description 2
- 229960000735 docosanol Drugs 0.000 claims description 2
- KIWBPDUYBMNFTB-UHFFFAOYSA-M ethyl sulfate Chemical compound CCOS([O-])(=O)=O KIWBPDUYBMNFTB-UHFFFAOYSA-M 0.000 claims description 2
- 150000002430 hydrocarbons Chemical class 0.000 claims description 2
- 229940055577 oleyl alcohol Drugs 0.000 claims description 2
- 229920002545 silicone oil Polymers 0.000 claims description 2
- 229920000728 polyester Polymers 0.000 claims 3
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 claims 2
- 229920000691 Poly[bis(2-chloroethyl) ether-alt-1,3-bis[3-(dimethylamino)propyl]urea] Polymers 0.000 claims 2
- AOPDRZXCEAKHHW-UHFFFAOYSA-N 1-pentoxypentane Chemical compound CCCCCOCCCCC AOPDRZXCEAKHHW-UHFFFAOYSA-N 0.000 claims 1
- 235000017858 Laurus nobilis Nutrition 0.000 claims 1
- 240000001422 Laurus nobilis Species 0.000 claims 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N Retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 claims 1
- 239000001273 butane Substances 0.000 claims 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- VGEWEGHHYWGXGG-UHFFFAOYSA-N ethyl N-hydroxycarbamate Chemical compound CCOC(=O)NO VGEWEGHHYWGXGG-UHFFFAOYSA-N 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 229920001296 polysiloxane Polymers 0.000 claims 1
- 230000000644 propagated Effects 0.000 claims 1
- CZMAXQOXGAWNDO-UHFFFAOYSA-N propane-1,1,2-triol Chemical class CC(O)C(O)O CZMAXQOXGAWNDO-UHFFFAOYSA-N 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N silicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 31
- 239000004615 ingredient Substances 0.000 description 26
- 239000000463 material Substances 0.000 description 22
- 235000010980 cellulose Nutrition 0.000 description 21
- 239000012071 phase Substances 0.000 description 17
- 235000014113 dietary fatty acids Nutrition 0.000 description 16
- 239000000194 fatty acid Substances 0.000 description 16
- 235000019198 oils Nutrition 0.000 description 15
- 206010000496 Acne Diseases 0.000 description 14
- 150000004665 fatty acids Chemical class 0.000 description 13
- 239000002480 mineral oil Substances 0.000 description 13
- 235000010446 mineral oil Nutrition 0.000 description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 13
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical class O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 11
- 229960003276 erythromycin Drugs 0.000 description 10
- 235000011187 glycerol Nutrition 0.000 description 9
- 229960005150 glycerol Drugs 0.000 description 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 9
- 229920002553 poly(2-methacrylolyloxyethyltrimethylammonium chloride) polymer Polymers 0.000 description 9
- WERYXYBDKMZEQL-UHFFFAOYSA-N 1,4-Butanediol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 8
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 8
- 229940015001 Glycerin Drugs 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 8
- ZGTMUACCHSMWAC-UHFFFAOYSA-L disodium;2-[2-[carboxylatomethyl(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetate Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 8
- 239000003205 fragrance Substances 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 7
- ZQCIPRGNRQXXSK-UHFFFAOYSA-N 1-octadecoxypropan-2-ol Chemical compound CCCCCCCCCCCCCCCCCCOCC(C)O ZQCIPRGNRQXXSK-UHFFFAOYSA-N 0.000 description 7
- REZZEXDLIUJMMS-UHFFFAOYSA-M Dimethyldioctadecylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC REZZEXDLIUJMMS-UHFFFAOYSA-M 0.000 description 7
- 229960004873 LEVOMENTHOL Drugs 0.000 description 7
- 229940041616 Menthol Drugs 0.000 description 7
- 150000001298 alcohols Chemical class 0.000 description 7
- 230000003255 anti-acne Effects 0.000 description 7
- 239000004664 distearyldimethylammonium chloride (DHTDMAC) Substances 0.000 description 7
- 235000013772 propylene glycol Nutrition 0.000 description 7
- 240000007170 Cocos nucifera Species 0.000 description 6
- 235000013162 Cocos nucifera Nutrition 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 6
- 125000005442 diisocyanate group Chemical group 0.000 description 6
- 238000006116 polymerization reaction Methods 0.000 description 6
- HSEXOZXVUZVSDZ-UHFFFAOYSA-N 2-[2-ethylhexyl(methyl)amino]benzoic acid Chemical compound CCCCC(CC)CN(C)C1=CC=CC=C1C(O)=O HSEXOZXVUZVSDZ-UHFFFAOYSA-N 0.000 description 5
- 229940078491 PPG-15 stearyl ether Drugs 0.000 description 5
- 239000011149 active material Substances 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 230000000996 additive Effects 0.000 description 5
- 230000000845 anti-microbial Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 229920000570 polyether Polymers 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 238000009834 vaporization Methods 0.000 description 5
- ATVJXMYDOSMEPO-UHFFFAOYSA-N 3-prop-2-enoxyprop-1-ene Chemical compound C=CCOCC=C ATVJXMYDOSMEPO-UHFFFAOYSA-N 0.000 description 4
- WSSJONWNBBTCMG-UHFFFAOYSA-N Homosalate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 description 4
- 229960004881 Homosalate Drugs 0.000 description 4
- BTSZTGGZJQFALU-UHFFFAOYSA-N Piroctone olamine Chemical class NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- OFVLGDICTFRJMM-WESIUVDSSA-N Tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 4
- 229960002180 Tetracycline Drugs 0.000 description 4
- 239000004098 Tetracycline Substances 0.000 description 4
- 235000019864 coconut oil Nutrition 0.000 description 4
- 239000003240 coconut oil Substances 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 235000021317 phosphate Nutrition 0.000 description 4
- 229950001046 piroctone Drugs 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 230000037072 sun protection Effects 0.000 description 4
- 239000000516 sunscreening agent Substances 0.000 description 4
- 235000019364 tetracycline Nutrition 0.000 description 4
- 230000001225 therapeutic Effects 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- OIQXFRANQVWXJF-QBFSEMIESA-N (2Z)-2-benzylidene-4,7,7-trimethylbicyclo[2.2.1]heptan-3-one Chemical compound CC1(C)C2CCC1(C)C(=O)\C2=C/C1=CC=CC=C1 OIQXFRANQVWXJF-QBFSEMIESA-N 0.000 description 3
- WSEBKJRVPMLGFV-UHFFFAOYSA-M (3-chloro-2-hydroxypropyl)-(2-hydroxyethyl)-dimethylazanium;chloride Chemical compound [Cl-].OCC[N+](C)(C)CC(O)CCl WSEBKJRVPMLGFV-UHFFFAOYSA-M 0.000 description 3
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 3
- 229940022659 Acetaminophen Drugs 0.000 description 3
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 3
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl methoxycinnamate Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 3
- 239000004698 Polyethylene (PE) Substances 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 239000004721 Polyphenylene oxide Substances 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229940046282 Zinc Drugs 0.000 description 3
- 229940091251 Zinc Supplements Drugs 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000000843 anti-fungal Effects 0.000 description 3
- 230000003110 anti-inflammatory Effects 0.000 description 3
- 230000001153 anti-wrinkle Effects 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 229960002255 azelaic acid Drugs 0.000 description 3
- 239000000084 colloidal system Substances 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- NTLIJZACUWTZFB-UHFFFAOYSA-N dimethyl-[3-(octadecanoylamino)propyl]azanium;2-hydroxypropanoate Chemical compound CC(O)C(O)=O.CCCCCCCCCCCCCCCCCC(=O)NCCCN(C)C NTLIJZACUWTZFB-UHFFFAOYSA-N 0.000 description 3
- LVXUNJWLKCUTNF-UHFFFAOYSA-N dimethyl-[3-(octadecanoylamino)propyl]azanium;chloride Chemical compound Cl.CCCCCCCCCCCCCCCCCC(=O)NCCCN(C)C LVXUNJWLKCUTNF-UHFFFAOYSA-N 0.000 description 3
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 3
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 229940079593 drugs Drugs 0.000 description 3
- ZWVMLYRJXORSEP-UHFFFAOYSA-N hexane-1,2,6-triol Chemical compound OCCCCC(O)CO ZWVMLYRJXORSEP-UHFFFAOYSA-N 0.000 description 3
- 229920001519 homopolymer Polymers 0.000 description 3
- CERQOIWHTDAKMF-UHFFFAOYSA-N methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 3
- 229960002509 miconazole Drugs 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N p-acetaminophenol Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- 229960005489 paracetamol Drugs 0.000 description 3
- 230000000737 periodic Effects 0.000 description 3
- 229920000058 polyacrylate Polymers 0.000 description 3
- 229920001888 polyacrylic acid Polymers 0.000 description 3
- 229920001515 polyalkylene glycol Polymers 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 230000000475 sunscreen Effects 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 150000003673 urethanes Chemical class 0.000 description 3
- DHPRQBPJLMKORJ-XRNKAMNCSA-N (4S,4aS,5aS,6S,12aR)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O DHPRQBPJLMKORJ-XRNKAMNCSA-N 0.000 description 2
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- XXMIOPMDWAUFGU-UHFFFAOYSA-N 1,6-Hexanediol Chemical compound OCCCCCCO XXMIOPMDWAUFGU-UHFFFAOYSA-N 0.000 description 2
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 2
- WXZMFSXDPGVJKK-UHFFFAOYSA-N 2,2-bis(hydroxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 2
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 2
- UVCJGUGAGLDPAA-UHFFFAOYSA-N 2-phenyl-3H-benzimidazole-5-sulfonic acid Chemical compound N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 description 2
- IJFXRHURBJZNAO-UHFFFAOYSA-N 3-Hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC(O)=C1 IJFXRHURBJZNAO-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-Aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-Hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- HEOCBCNFKCOKBX-SDNWHVSQSA-N 4-Methylbenzylidene camphor Chemical compound C1=CC(C)=CC=C1\C=C/1C(=O)C2(C)CCC\1C2(C)C HEOCBCNFKCOKBX-SDNWHVSQSA-N 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N Behenic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- 239000004342 Benzoyl peroxide Substances 0.000 description 2
- DSSYKIVIOFKYAU-UHFFFAOYSA-N Camphor Chemical compound C1CC2(C)C(=O)CC1C2(C)C DSSYKIVIOFKYAU-UHFFFAOYSA-N 0.000 description 2
- 229960000846 Camphor Drugs 0.000 description 2
- 229960004475 Chlortetracycline Drugs 0.000 description 2
- 239000004099 Chlortetracycline Substances 0.000 description 2
- 241000723346 Cinnamomum camphora Species 0.000 description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N Clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N Diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
- SDIXRDNYIMOKSG-UHFFFAOYSA-L Disodium methyl arsenate Chemical compound [Na+].[Na+].C[As]([O-])([O-])=O SDIXRDNYIMOKSG-UHFFFAOYSA-L 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N Eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Incidol Chemical class C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- 229940001447 Lactate Drugs 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N Linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 229940096956 PPG-11 STEARYL ETHER Drugs 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N Palmitic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 2
- ICUTUKXCWQYESQ-UHFFFAOYSA-N Triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002378 acidificating Effects 0.000 description 2
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 2
- 125000002877 alkyl aryl group Chemical group 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 229960004050 aminobenzoic acid Drugs 0.000 description 2
- 230000003712 anti-aging Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000005418 aryl aryl group Chemical group 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N benzohydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 229960003328 benzoyl peroxide Drugs 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 2
- 229930007890 camphor Natural products 0.000 description 2
- 229920003086 cellulose ether Polymers 0.000 description 2
- 235000019365 chlortetracycline Nutrition 0.000 description 2
- 229960002227 clindamycin Drugs 0.000 description 2
- 239000008406 cosmetic ingredient Substances 0.000 description 2
- WLCFKPHMRNPAFZ-UHFFFAOYSA-M didodecyl(dimethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCC WLCFKPHMRNPAFZ-UHFFFAOYSA-M 0.000 description 2
- KIQKWYUGPPFMBV-UHFFFAOYSA-N diisocyanatomethane Chemical class O=C=NCN=C=O KIQKWYUGPPFMBV-UHFFFAOYSA-N 0.000 description 2
- RSHHCURRBLAGFA-UHFFFAOYSA-M dimethyl-di(tetradecyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCC RSHHCURRBLAGFA-UHFFFAOYSA-M 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- PGQAXGHQYGXVDC-UHFFFAOYSA-N dodecyl(dimethyl)azanium;chloride Chemical compound Cl.CCCCCCCCCCCCN(C)C PGQAXGHQYGXVDC-UHFFFAOYSA-N 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 150000004676 glycans Polymers 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 125000001145 hydrido group Chemical group *[H] 0.000 description 2
- VAMFXQBUQXONLZ-UHFFFAOYSA-N icos-1-ene Chemical compound CCCCCCCCCCCCCCCCCCC=C VAMFXQBUQXONLZ-UHFFFAOYSA-N 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 229960003742 phenol Drugs 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 150000004804 polysaccharides Polymers 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 230000037335 skin penetration Effects 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- RUELTTOHQODFPA-UHFFFAOYSA-N toluene 2,6-diisocyanate Chemical class CC1=C(N=C=O)C=CC=C1N=C=O RUELTTOHQODFPA-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical Effects 0.000 description 2
- QYKIQEUNHZKYBP-UHFFFAOYSA-N vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N α-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- VQOXZBDYSJBXMA-NQTDYLQESA-N (1S,3R,4E,6E,8E,10E,14E,16E,18S,19R,20R,21S,25R,27R,29R,32R,33R,35S,37S,38R)-3-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,29,32,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,14, Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- AGFWIZQEWFGATK-UNZHCMSXSA-N (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4-amino-3-[[(2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;sulfuric acid Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](NC)[C@@](C)(O)CO1)O)NCC)[C@H]1OC(CN)=CC[C@H]1N.O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](NC)[C@@](C)(O)CO1)O)NCC)[C@H]1OC(CN)=CC[C@H]1N AGFWIZQEWFGATK-UNZHCMSXSA-N 0.000 description 1
- ZKIRNCACNZXACZ-VFQQELCFSA-N (2R,3R,4R,5S)-hexane-1,2,3,4,5,6-hexol;propane-1,2,3-triol Chemical compound OCC(O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO ZKIRNCACNZXACZ-VFQQELCFSA-N 0.000 description 1
- VCOPTHOUUNAYKQ-WBTCAYNUSA-N (3S)-3,6-diamino-N-[[(2S,5S,8E,11S,15S)-15-amino-11-[(6R)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3S)-3,6-diamino-N-[[(2S,5S,8 Chemical compound N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1.N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1 VCOPTHOUUNAYKQ-WBTCAYNUSA-N 0.000 description 1
- VXPSARQTYDZXAO-CCHMMTNSSA-N (4S,4aR,5S,5aR,12aR)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydron;chloride Chemical compound Cl.C=C1C2=CC=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O VXPSARQTYDZXAO-CCHMMTNSSA-N 0.000 description 1
- PTNZGHXUZDHMIQ-CVHRZJFOSA-N (4S,4aR,5S,5aR,6R,12aR)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O PTNZGHXUZDHMIQ-CVHRZJFOSA-N 0.000 description 1
- SVDOODSCHVSYEK-IFLJXUKPSA-N (4S,4aR,5S,5aR,6S,12aR)-4-(dimethylamino)-1,5,6,10,11,12a-hexahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydron;chloride Chemical compound Cl.C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O SVDOODSCHVSYEK-IFLJXUKPSA-N 0.000 description 1
- YCIHPQHVWDULOY-FMZCEJRJSA-N (4S,4aS,5aS,6S,12aR)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O YCIHPQHVWDULOY-FMZCEJRJSA-N 0.000 description 1
- JXNPEDYJTDQORS-AVQMFFATSA-N (9E,12E)-octadeca-9,12-dien-1-ol Chemical compound CCCCC\C=C\C\C=C\CCCCCCCCO JXNPEDYJTDQORS-AVQMFFATSA-N 0.000 description 1
- QLLUAUADIMPKIH-UHFFFAOYSA-N 1,2-bis(ethenyl)naphthalene Chemical compound C1=CC=CC2=C(C=C)C(C=C)=CC=C21 QLLUAUADIMPKIH-UHFFFAOYSA-N 0.000 description 1
- ZTNJGMFHJYGMDR-UHFFFAOYSA-N 1,2-diisocyanatoethane Chemical compound O=C=NCCN=C=O ZTNJGMFHJYGMDR-UHFFFAOYSA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-Propanediol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- RTTZISZSHSCFRH-UHFFFAOYSA-N 1,3-bis(isocyanatomethyl)benzene Chemical compound O=C=NCC1=CC=CC(CN=C=O)=C1 RTTZISZSHSCFRH-UHFFFAOYSA-N 0.000 description 1
- VGHSXKTVMPXHNG-UHFFFAOYSA-N 1,3-diisocyanatobenzene Chemical compound O=C=NC1=CC=CC(N=C=O)=C1 VGHSXKTVMPXHNG-UHFFFAOYSA-N 0.000 description 1
- OHLKMGYGBHFODF-UHFFFAOYSA-N 1,4-bis(isocyanatomethyl)benzene Chemical compound O=C=NCC1=CC=C(CN=C=O)C=C1 OHLKMGYGBHFODF-UHFFFAOYSA-N 0.000 description 1
- ALQLPWJFHRMHIU-UHFFFAOYSA-N 1,4-diisocyanatobenzene Chemical compound O=C=NC1=CC=C(N=C=O)C=C1 ALQLPWJFHRMHIU-UHFFFAOYSA-N 0.000 description 1
- SBJCUZQNHOLYMD-UHFFFAOYSA-N 1,5-Naphthalene diisocyanate Chemical compound C1=CC=C2C(N=C=O)=CC=CC2=C1N=C=O SBJCUZQNHOLYMD-UHFFFAOYSA-N 0.000 description 1
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N 1-Tetradecanol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 1
- SZBXTBGNJLZMHB-UHFFFAOYSA-N 1-chloro-2,4-diisocyanatobenzene Chemical compound ClC1=CC=C(N=C=O)C=C1N=C=O SZBXTBGNJLZMHB-UHFFFAOYSA-N 0.000 description 1
- ICLCCFKUSALICQ-UHFFFAOYSA-N 1-isocyanato-4-(4-isocyanato-3-methylphenyl)-2-methylbenzene Chemical compound C1=C(N=C=O)C(C)=CC(C=2C=C(C)C(N=C=O)=CC=2)=C1 ICLCCFKUSALICQ-UHFFFAOYSA-N 0.000 description 1
- TWNLLIFNDPYUTQ-UHFFFAOYSA-N 1-tert-butyl-2,4-diisocyanatobenzene Chemical compound CC(C)(C)C1=CC=C(N=C=O)C=C1N=C=O TWNLLIFNDPYUTQ-UHFFFAOYSA-N 0.000 description 1
- BCZJWMRBYAAKKL-UHFFFAOYSA-N 2,3-dihydroxypropyl-dimethyl-[3-(octadecanoylamino)propyl]azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC(O)CO BCZJWMRBYAAKKL-UHFFFAOYSA-N 0.000 description 1
- DZDVHNPXFWWDRM-UHFFFAOYSA-N 2,4-diisocyanato-1-methoxybenzene Chemical compound COC1=CC=C(N=C=O)C=C1N=C=O DZDVHNPXFWWDRM-UHFFFAOYSA-N 0.000 description 1
- JDYCXZOXTYYKNP-UHFFFAOYSA-N 2,4-diisocyanato-1-phenoxybenzene Chemical compound O=C=NC1=CC(N=C=O)=CC=C1OC1=CC=CC=C1 JDYCXZOXTYYKNP-UHFFFAOYSA-N 0.000 description 1
- POAOYUHQDCAZBD-UHFFFAOYSA-N 2-Butoxyethanol Chemical compound CCCCOCCO POAOYUHQDCAZBD-UHFFFAOYSA-N 0.000 description 1
- AFENDNXGAFYKQO-UHFFFAOYSA-N 2-Hydroxybutyric acid Chemical compound CCC(O)C(O)=O AFENDNXGAFYKQO-UHFFFAOYSA-N 0.000 description 1
- HMOLBIVDTAELCU-UHFFFAOYSA-N 2-[(4-ethylphenyl)methylidene]-4,7,7-trimethylbicyclo[2.2.1]heptan-3-one Chemical compound C1=CC(CC)=CC=C1C=C1C(=O)C2(C)CCC1C2(C)C HMOLBIVDTAELCU-UHFFFAOYSA-N 0.000 description 1
- AKWFJQNBHYVIPY-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO AKWFJQNBHYVIPY-UHFFFAOYSA-N 0.000 description 1
- WIXIDJHPZOYPSW-UHFFFAOYSA-N 2-[4-(1-hydroxypropan-2-yloxy)butoxy]propan-1-ol Chemical compound OCC(C)OCCCCOC(C)CO WIXIDJHPZOYPSW-UHFFFAOYSA-N 0.000 description 1
- TYCOFFBAZNSQOJ-UHFFFAOYSA-N 2-[4-(3-fluorophenyl)phenyl]propanoic acid Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC(F)=C1 TYCOFFBAZNSQOJ-UHFFFAOYSA-N 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N 2-[6-[[amino-[[amino-(4-chloroanilino)methylidene]amino]methylidene]amino]hexyl]-1-[amino-(4-chloroanilino)methylidene]guanidine;hydron;dichloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- OBWBSSIUKXEALB-UHFFFAOYSA-N 2-aminoethanol;2-hydroxypropanamide Chemical compound NCCO.CC(O)C(N)=O OBWBSSIUKXEALB-UHFFFAOYSA-N 0.000 description 1
- UKCFWUCWNZTUPT-UHFFFAOYSA-N 2-dodecoxypropan-1-ol Chemical compound CCCCCCCCCCCCOC(C)CO UKCFWUCWNZTUPT-UHFFFAOYSA-N 0.000 description 1
- WROUWQQRXUBECT-UHFFFAOYSA-N 2-ethylacrylic acid Chemical compound CCC(=C)C(O)=O WROUWQQRXUBECT-UHFFFAOYSA-N 0.000 description 1
- UPGSWASWQBLSKZ-UHFFFAOYSA-N 2-hexoxyethanol Chemical compound CCCCCCOCCO UPGSWASWQBLSKZ-UHFFFAOYSA-N 0.000 description 1
- NYHNVHGFPZAZGA-UHFFFAOYSA-N 2-hydroxyhexanoic acid Chemical compound CCCCC(O)C(O)=O NYHNVHGFPZAZGA-UHFFFAOYSA-N 0.000 description 1
- JRHWHSJDIILJAT-UHFFFAOYSA-N 2-hydroxypentanoic acid Chemical compound CCCC(O)C(O)=O JRHWHSJDIILJAT-UHFFFAOYSA-N 0.000 description 1
- KIHBGTRZFAVZRV-UHFFFAOYSA-N 2-hydroxystearic acid Chemical compound CCCCCCCCCCCCCCCCC(O)C(O)=O KIHBGTRZFAVZRV-UHFFFAOYSA-N 0.000 description 1
- DWYHDSLIWMUSOO-UHFFFAOYSA-N 2-phenyl-1H-benzimidazole Chemical compound C1=CC=CC=C1C1=NC2=CC=CC=C2N1 DWYHDSLIWMUSOO-UHFFFAOYSA-N 0.000 description 1
- ILYSAKHOYBPSPC-UHFFFAOYSA-N 2-phenylbenzoic acid Chemical class OC(=O)C1=CC=CC=C1C1=CC=CC=C1 ILYSAKHOYBPSPC-UHFFFAOYSA-N 0.000 description 1
- QZWKEPYTBWZJJA-UHFFFAOYSA-N 3,3'-Dimethoxybenzidine-4,4'-diisocyanate Chemical compound C1=C(N=C=O)C(OC)=CC(C=2C=C(OC)C(N=C=O)=CC=2)=C1 QZWKEPYTBWZJJA-UHFFFAOYSA-N 0.000 description 1
- VRORTNGXAKZJML-UHFFFAOYSA-N 3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoic acid Chemical compound IC1=CC(CCC(=O)O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 VRORTNGXAKZJML-UHFFFAOYSA-N 0.000 description 1
- YDIYEOMDOWUDTJ-UHFFFAOYSA-M 4-(dimethylamino)benzoate Chemical compound CN(C)C1=CC=C(C([O-])=O)C=C1 YDIYEOMDOWUDTJ-UHFFFAOYSA-M 0.000 description 1
- BHQCQFFYRZLCQQ-UMZBRFQRSA-N 4-[(3R,5S,7R,12S)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid Chemical class C([C@H]1C[C@H]2O)[C@H](O)CCC1(C)C1C2C2CCC(C(CCC(O)=O)C)C2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-UMZBRFQRSA-N 0.000 description 1
- SUXLANSZRSDYOX-UHFFFAOYSA-N 4-[6-(4-carbamimidoylphenoxy)hexoxy]benzenecarboximidamide;2-hydroxyethanesulfonic acid Chemical compound OCCS(O)(=O)=O.C1=CC(C(=N)N)=CC=C1OCCCCCCOC1=CC=C(C(N)=N)C=C1 SUXLANSZRSDYOX-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- BDQHDFBEAFMWII-UHFFFAOYSA-N 6-hydroxyhexanal;hydrochloride Chemical compound Cl.OCCCCCC=O BDQHDFBEAFMWII-UHFFFAOYSA-N 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L 7681-57-4 Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940086737 ALLYL SUCROSE Drugs 0.000 description 1
- 229960000458 Allantoin Drugs 0.000 description 1
- FPHLBGOJWPEVME-UHFFFAOYSA-N Alminoprofen Chemical compound OC(=O)C(C)C1=CC=C(NCC(C)=C)C=C1 FPHLBGOJWPEVME-UHFFFAOYSA-N 0.000 description 1
- 229960001656 Amikacin Sulfate Drugs 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 229940114079 Arachidonic Acid Drugs 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-N Arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 229940093761 Bile Salts Drugs 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N Bupivacaine Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- PUDHBTGHUJUUFI-PURAGXGVSA-N CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)NC(=O)[C@@H](N)CC1=CC=C2C=CC=CC2=C1 Chemical group CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)NC(=O)[C@@H](N)CC1=CC=C2C=CC=CC2=C1 PUDHBTGHUJUUFI-PURAGXGVSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Calypsol Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- JNIIDKODPGHQSS-DHDCSXOGSA-N Capreomycin Chemical compound N1C(=O)\C(=C\NC(N)=O)NC(=O)C(CNC(=O)CC(N)CCCN)NC(=O)C(CO)NC(=O)C(N)CNC(=O)C1C1NC(N)=NCC1 JNIIDKODPGHQSS-DHDCSXOGSA-N 0.000 description 1
- 108010065839 Capreomycin Proteins 0.000 description 1
- 229960002968 Capreomycin Sulfate Drugs 0.000 description 1
- 229960001631 Carbomer Drugs 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N Carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- WOWHHFRSBJGXCM-UHFFFAOYSA-M Cetrimonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
- 229960003260 Chlorhexidine Drugs 0.000 description 1
- 229960004504 Chlorhexidine Hydrochloride Drugs 0.000 description 1
- 229960002023 Chloroprocaine Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N Chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N Cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N Cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- MYSWGUAQZAJSOK-UHFFFAOYSA-N Ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 1
- HGCIXCUEYOPUTN-UHFFFAOYSA-N Cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical class OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-α-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 229960004082 DOXYCYCLINE HYDROCHLORIDE Drugs 0.000 description 1
- 229940009976 Deoxycholate Drugs 0.000 description 1
- 239000005696 Diammonium phosphate Substances 0.000 description 1
- 229940120099 Dibucaine Drugs 0.000 description 1
- 240000008570 Digitaria exilis Species 0.000 description 1
- 235000005459 Digitaria exilis Nutrition 0.000 description 1
- RXKJFZQQPQGTFL-UHFFFAOYSA-N Dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 1
- 229940120503 Dihydroxyacetone Drugs 0.000 description 1
- UPMLOUAZCHDJJD-UHFFFAOYSA-N Diphenylmethane p,p'-diisocyanate Chemical compound C1=CC(N=C=O)=CC=C1CC1=CC=C(N=C=O)C=C1 UPMLOUAZCHDJJD-UHFFFAOYSA-N 0.000 description 1
- 229940113120 Dipropylene Glycol Drugs 0.000 description 1
- 229960003722 Doxycycline Drugs 0.000 description 1
- 229960000385 Dyclonine Drugs 0.000 description 1
- BZEWSEKUUPWQDQ-UHFFFAOYSA-N Dyclonine Chemical compound C1=CC(OCCCC)=CC=C1C(=O)CCN1CCCCC1 BZEWSEKUUPWQDQ-UHFFFAOYSA-N 0.000 description 1
- 229960003203 Erythromycin Estolate Drugs 0.000 description 1
- AEUTYOVWOVBAKS-UWVGGRQHSA-N Ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 1
- 229960000285 Ethambutol Drugs 0.000 description 1
- 229960001618 Ethambutol Hydrochloride Drugs 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 229960003976 Etidocaine Drugs 0.000 description 1
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 description 1
- 229940044949 Eucalyptus oil Drugs 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 229960002217 Eugenol Drugs 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Exidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N Fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- 229960001419 Fenoprofen Drugs 0.000 description 1
- RDJGLLICXDHJDY-UHFFFAOYSA-N Fenoprofen Chemical compound OC(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-UHFFFAOYSA-N 0.000 description 1
- 229950001284 Fluprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N Flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N Glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 1
- 229940015043 Glyoxal Drugs 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- ROAIXOJGRFKICW-UHFFFAOYSA-N Haiprex Chemical compound C1N(C2)CN3CN1CN2C3.OC(=O)CNC(=O)C1=CC=CC=C1 ROAIXOJGRFKICW-UHFFFAOYSA-N 0.000 description 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N Hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
- UXNFIJPHRQEWRQ-UHFFFAOYSA-N Hexamethylenetetramine mandelate salt Chemical compound C1N(C2)CN3CN1CN2C3.OC(=O)C(O)C1=CC=CC=C1 UXNFIJPHRQEWRQ-UHFFFAOYSA-N 0.000 description 1
- DKLKMKYDWHYZTD-UHFFFAOYSA-N Hexylcaine Chemical compound C=1C=CC=CC=1C(=O)OC(C)CNC1CCCCC1 DKLKMKYDWHYZTD-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- RJMIEHBSYVWVIN-UHFFFAOYSA-N Indoprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-UHFFFAOYSA-N 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N Kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N Ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 229960004393 Lidocaine Hydrochloride Drugs 0.000 description 1
- 229960004488 Linolenic Acid Drugs 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N Maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- MHIGBKBJSQVXNH-IWVLMIASSA-N Metacycline Chemical compound C=C([C@H]1[C@@H]2O)C3=CC=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O MHIGBKBJSQVXNH-IWVLMIASSA-N 0.000 description 1
- FQPSGWSUVKBHSU-UHFFFAOYSA-N Methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 1
- 229960004011 Methenamine Drugs 0.000 description 1
- XJRBAMWJDBPFIM-UHFFFAOYSA-N Methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 1
- VOEYXMAFNDNNED-UHFFFAOYSA-N Metolcarb Chemical compound CNC(=O)OC1=CC=CC(C)=C1 VOEYXMAFNDNNED-UHFFFAOYSA-N 0.000 description 1
- 229960000282 Metronidazole Drugs 0.000 description 1
- 229960002395 Metronidazole Hydrochloride Drugs 0.000 description 1
- 229960004023 Minocycline Drugs 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N Minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- 229960002421 Minocycline Hydrochloride Drugs 0.000 description 1
- OJGQFYYLKNCIJD-UHFFFAOYSA-N Miroprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C1=CN(C=CC=C2)C2=N1 OJGQFYYLKNCIJD-UHFFFAOYSA-N 0.000 description 1
- 229950006616 Miroprofen Drugs 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- QMDUPVPMPVZZGK-UHFFFAOYSA-N N,N-dimethyloctadecan-1-amine;hydrobromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[NH+](C)C QMDUPVPMPVZZGK-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- ALQWDAJTEFASRJ-UHFFFAOYSA-N N-hexadecylhexadecan-1-amine;hydrochloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[NH2+]CCCCCCCCCCCCCCCC ALQWDAJTEFASRJ-UHFFFAOYSA-N 0.000 description 1
- WVMBPWMAQDVZCM-UHFFFAOYSA-N N-methylanthranilic acid Chemical compound CNC1=CC=CC=C1C(O)=O WVMBPWMAQDVZCM-UHFFFAOYSA-N 0.000 description 1
- FFJMLWSZNCJCSZ-UHFFFAOYSA-N N-methylmethanamine;hydrobromide Chemical compound Br.CNC FFJMLWSZNCJCSZ-UHFFFAOYSA-N 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N Neomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- 229940053050 Neomycin Sulfate Drugs 0.000 description 1
- 229960004832 Netilmicin Sulfate Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N Norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001180 Norfloxacin Drugs 0.000 description 1
- 229960002969 Oleic Acid Drugs 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- MITFXPHMIHQXPI-UHFFFAOYSA-N Oraflex Chemical compound N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N Oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 description 1
- 229960000625 Oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N Oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 229960004368 Oxytetracycline Hydrochloride Drugs 0.000 description 1
- 229940078492 PPG-17 Drugs 0.000 description 1
- WYWZRNAHINYAEF-UHFFFAOYSA-N Padimate O Chemical compound CCCCC(CC)COC(=O)C1=CC=C(N(C)C)C=C1 WYWZRNAHINYAEF-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 229940101267 Panthenol Drugs 0.000 description 1
- 229940055726 Pantothenic Acid Drugs 0.000 description 1
- XDRYMKDFEDOLFX-UHFFFAOYSA-N Pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
- 229960004448 Pentamidine Drugs 0.000 description 1
- PIDSZXPFGCURGN-UHFFFAOYSA-N Pirprofen Chemical compound ClC1=CC(C(C(O)=O)C)=CC=C1N1CC=CC1 PIDSZXPFGCURGN-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001748 Polybutylene Polymers 0.000 description 1
- 229920000289 Polyquaternium Polymers 0.000 description 1
- DQKXQSGTHWVTAD-UHFFFAOYSA-N Pramocaine Chemical compound C1=CC(OCCCC)=CC=C1OCCCN1CCOCC1 DQKXQSGTHWVTAD-UHFFFAOYSA-N 0.000 description 1
- TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- WBHHMMIMDMUBKC-QJWNTBNXSA-N Ricinoleic acid Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(O)=O WBHHMMIMDMUBKC-QJWNTBNXSA-N 0.000 description 1
- WBHHMMIMDMUBKC-GKUQOKNUSA-N Ricinoleic acid Natural products CCCCCC[C@H](O)C\C=C/CCCCCCCC(O)=O WBHHMMIMDMUBKC-GKUQOKNUSA-N 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229960005322 Streptomycin Drugs 0.000 description 1
- 229960002385 Streptomycin Sulfate Drugs 0.000 description 1
- 229960004492 Suprofen Drugs 0.000 description 1
- MDKGKXOCJGEUJW-UHFFFAOYSA-N Suprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-UHFFFAOYSA-N 0.000 description 1
- 229960002372 Tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N Tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N Tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 229960004477 Tobramycin Sulfate Drugs 0.000 description 1
- 229960001295 Tocopherol Drugs 0.000 description 1
- 229940042585 Tocopherol Acetate Drugs 0.000 description 1
- FUSNMLFNXJSCDI-UHFFFAOYSA-N Tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 description 1
- DVKJHBMWWAPEIU-UHFFFAOYSA-N Toluene diisocyanate Chemical compound CC1=CC=C(N=C=O)C=C1N=C=O DVKJHBMWWAPEIU-UHFFFAOYSA-N 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N Triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- 230000037338 UVA radiation Effects 0.000 description 1
- 210000002700 Urine Anatomy 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Xylocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- UOZODPSAJZTQNH-LSWIJEOBSA-N Zygomycin A1 Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 description 1
- SCMSRHIBVBIECI-UHFFFAOYSA-N [2-hydroxy-4-(2-hydroxyethoxy)phenyl]-phenylmethanone Chemical compound OC1=CC(OCCO)=CC=C1C(=O)C1=CC=CC=C1 SCMSRHIBVBIECI-UHFFFAOYSA-N 0.000 description 1
- CCZVXFBLXWMWCA-UHFFFAOYSA-M [Cl-].C(CCCCCCCCCCCCCCCCC)[NH-] Chemical compound [Cl-].C(CCCCCCCCCCCCCCCCC)[NH-] CCZVXFBLXWMWCA-UHFFFAOYSA-M 0.000 description 1
- OSSCGHSWPYDTQZ-UHFFFAOYSA-N [Cl-].[NH4+].C(CCCCCCCCCCCCC)CC(=O)[O-].[NH4+] Chemical compound [Cl-].[NH4+].C(CCCCCCCCCCCCC)CC(=O)[O-].[NH4+] OSSCGHSWPYDTQZ-UHFFFAOYSA-N 0.000 description 1
- PZITWUYIDYHVJZ-UHFFFAOYSA-O [NH4+].CCCCCCCCCCCCCCOC(C)=O Chemical compound [NH4+].CCCCCCCCCCCCCCOC(C)=O PZITWUYIDYHVJZ-UHFFFAOYSA-O 0.000 description 1
- SZQVPFAWVOAHPI-UHFFFAOYSA-N [O-]P([O-])([O-])=O.CCC[NH2+]CCC.CCC[NH2+]CCC.CCC[NH2+]CCC Chemical compound [O-]P([O-])([O-])=O.CCC[NH2+]CCC.CCC[NH2+]CCC.CCC[NH2+]CCC SZQVPFAWVOAHPI-UHFFFAOYSA-N 0.000 description 1
- DHFCLYNGVLPKPK-UHFFFAOYSA-N acetamide;2-aminoethanol Chemical compound CC(N)=O.NCCO DHFCLYNGVLPKPK-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- HGINCPLSRVDWNT-UHFFFAOYSA-N acrylaldehyde Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 229960004663 alminoprofen Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 229960001452 alpha-Tocopherol Acetate Drugs 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- FXKSEJFHKVNEFI-GCZBSULCSA-N amikacin disulfate Chemical compound [H+].[H+].[H+].[H+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O FXKSEJFHKVNEFI-GCZBSULCSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 229940111133 antiinflammatory and antirheumatic drugs Oxicams Drugs 0.000 description 1
- 229940111131 antiinflammatory and antirheumatic products Propionic acid derivatives Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 125000002511 behenyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960005430 benoxaprofen Drugs 0.000 description 1
- 150000001277 beta hydroxy acids Chemical class 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- KAKZBPTYRLMSJV-UHFFFAOYSA-N butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 1
- AXNCLTXKOHIWCA-UHFFFAOYSA-N butan-1-ol;propane-1,2-diol Chemical compound CCCCO.CC(O)CO AXNCLTXKOHIWCA-UHFFFAOYSA-N 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 229960004602 capreomycin Drugs 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- BYMMIQCVDHHYGG-UHFFFAOYSA-J chloride;phosphate Chemical compound [Cl-].[O-]P([O-])([O-])=O BYMMIQCVDHHYGG-UHFFFAOYSA-J 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 230000003750 conditioning Effects 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-M deoxycholate Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-M 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229910000388 diammonium phosphate Inorganic materials 0.000 description 1
- KORSJDCBLAPZEQ-UHFFFAOYSA-N dicyclohexylmethane-4,4'-diisocyanate Chemical compound C1CC(N=C=O)CCC1CC1CCC(N=C=O)CC1 KORSJDCBLAPZEQ-UHFFFAOYSA-N 0.000 description 1
- AATGHKSFEUVOPF-UHFFFAOYSA-N diethylazanium;bromide Chemical compound [Br-].CC[NH2+]CC AATGHKSFEUVOPF-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- PFKRTWCFCOUBHS-UHFFFAOYSA-N dimethyl(octadecyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[NH+](C)C PFKRTWCFCOUBHS-UHFFFAOYSA-N 0.000 description 1
- DKJLEUVQMKPSHB-UHFFFAOYSA-N dimethyl-[3-(octadecanoylamino)propyl]-(2-oxo-2-tetradecoxyethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCCCC DKJLEUVQMKPSHB-UHFFFAOYSA-N 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- QHNXEVRKFKHMRL-UHFFFAOYSA-N dimethylazanium;acetate Chemical compound CNC.CC(O)=O QHNXEVRKFKHMRL-UHFFFAOYSA-N 0.000 description 1
- KGOGNDXXUVELIQ-UHFFFAOYSA-N dioctadecylazanium;chloride Chemical compound Cl.CCCCCCCCCCCCCCCCCCNCCCCCCCCCCCCCCCCCC KGOGNDXXUVELIQ-UHFFFAOYSA-N 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 229950008690 docosanoic acid Drugs 0.000 description 1
- VZXFEELLBDNLAL-UHFFFAOYSA-N dodecan-1-amine;hydrobromide Chemical compound [Br-].CCCCCCCCCCCC[NH3+] VZXFEELLBDNLAL-UHFFFAOYSA-N 0.000 description 1
- TWFQJFPTTMIETC-UHFFFAOYSA-N dodecan-1-amine;hydron;chloride Chemical compound [Cl-].CCCCCCCCCCCC[NH3+] TWFQJFPTTMIETC-UHFFFAOYSA-N 0.000 description 1
- YWFWDNVOPHGWMX-UHFFFAOYSA-O dodecyl(dimethyl)azanium Chemical group CCCCCCCCCCCC[NH+](C)C YWFWDNVOPHGWMX-UHFFFAOYSA-O 0.000 description 1
- DLFDEDJIVYYWTB-UHFFFAOYSA-N dodecyl(dimethyl)azanium;bromide Chemical compound Br.CCCCCCCCCCCCN(C)C DLFDEDJIVYYWTB-UHFFFAOYSA-N 0.000 description 1
- DDXLVDQZPFLQMZ-UHFFFAOYSA-M dodecyl(trimethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)C DDXLVDQZPFLQMZ-UHFFFAOYSA-M 0.000 description 1
- XJWSAJYUBXQQDR-UHFFFAOYSA-M dodecyltrimethylammonium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)C XJWSAJYUBXQQDR-UHFFFAOYSA-M 0.000 description 1
- JBIWCJUYHHGXTC-AKNGSSGZSA-N doxycycline Chemical compound O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O JBIWCJUYHHGXTC-AKNGSSGZSA-N 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 150000002118 epoxides Chemical group 0.000 description 1
- AWMFUEJKWXESNL-JZBHMOKNSA-N erythromycin estolate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(=O)CC)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AWMFUEJKWXESNL-JZBHMOKNSA-N 0.000 description 1
- 229950001028 erythromycin propionate Drugs 0.000 description 1
- 229960004142 erythromycin stearate Drugs 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 125000002573 ethenylidene group Chemical group [*]=C=C([H])[H] 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- YNDMEEULGSTYJT-LURJTMIESA-N foslevodopa Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C(O)=C1 YNDMEEULGSTYJT-LURJTMIESA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- NMIYNWDARZCKJG-UHFFFAOYSA-N heptatriacontan-19-ylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCCC([NH3+])CCCCCCCCCCCCCCCCCC NMIYNWDARZCKJG-UHFFFAOYSA-N 0.000 description 1
- URXQDXAVUYKSCK-UHFFFAOYSA-N hexadecyl(dimethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[NH+](C)C URXQDXAVUYKSCK-UHFFFAOYSA-N 0.000 description 1
- ZWGTVKDEOPDFGW-UHFFFAOYSA-N hexadecylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[NH3+] ZWGTVKDEOPDFGW-UHFFFAOYSA-N 0.000 description 1
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- 229960001715 hexamidine isethionate Drugs 0.000 description 1
- QVTWBMUAJHVAIJ-UHFFFAOYSA-N hexane-1,4-diol Chemical compound CCC(O)CCCO QVTWBMUAJHVAIJ-UHFFFAOYSA-N 0.000 description 1
- 229960005388 hexylcaine Drugs 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- XPXMKIXDFWLRAA-UHFFFAOYSA-N hydrazinide Chemical class [NH-]N XPXMKIXDFWLRAA-UHFFFAOYSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 1
- 230000002209 hydrophobic Effects 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl radical Chemical class [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229960004187 indoprofen Drugs 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 230000001530 keratinolytic Effects 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229960002437 lanreotide Drugs 0.000 description 1
- 230000003902 lesions Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 229960004232 linoleic acid Drugs 0.000 description 1
- 125000002669 linoleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960003494 metacycline Drugs 0.000 description 1
- 229910052751 metal Chemical class 0.000 description 1
- 239000002184 metal Chemical class 0.000 description 1
- 229960003900 methenamine hippurate Drugs 0.000 description 1
- 229960002786 methenamine mandelate Drugs 0.000 description 1
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- FPTPAIQTXYFGJC-UHFFFAOYSA-N metronidazole hydrochloride Chemical compound Cl.CC1=NC=C([N+]([O-])=O)N1CCO FPTPAIQTXYFGJC-UHFFFAOYSA-N 0.000 description 1
- GLMUAFMGXXHGLU-VQAITOIOSA-N minocycline hydrochloride Chemical compound [H+].[Cl-].C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O GLMUAFMGXXHGLU-VQAITOIOSA-N 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N monochloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- YHIXOVNFGQWPFW-UHFFFAOYSA-N octadecan-1-amine;hydrobromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[NH3+] YHIXOVNFGQWPFW-UHFFFAOYSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N pantothenic acid Natural products OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 229960001914 paromomycin Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229960000851 pirprofen Drugs 0.000 description 1
- 229920001521 polyalkylene glycol ether Polymers 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229960001896 pramocaine Drugs 0.000 description 1
- 229960003101 pranoprofen Drugs 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 150000005599 propionic acid derivatives Chemical class 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2(1H)-one Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229960003656 ricinoleic acid Drugs 0.000 description 1
- 231100000197 serious side effect Toxicity 0.000 description 1
- 231100000051 skin sensitiser Toxicity 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000003381 solubilizing Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N sulfonic acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 150000005621 tetraalkylammonium salts Chemical class 0.000 description 1
- 229960004989 tetracycline hydrochloride Drugs 0.000 description 1
- UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 229950000464 thyropropic acid Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229930003799 tocopherols Natural products 0.000 description 1
- 229960004880 tolnaftate Drugs 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- SZEMGTQCPRNXEG-UHFFFAOYSA-M trimethyl(octadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C SZEMGTQCPRNXEG-UHFFFAOYSA-M 0.000 description 1
- 150000004072 triols Chemical class 0.000 description 1
- 150000003668 tyrosines Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- MNFORVFSTILPAW-UHFFFAOYSA-N Β-Lactam Chemical compound O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Abstract
The present invention relates to oil-in-water emulsion compositions, which are useful in personal cleansing and for depositing an active ingredient on the surface of the skin. The active ingredient in compositions has a solubility parameter of about 7 to about 13. A preferred active ingredient is salicylate.
Description
Wet stamp that says: Number of shipping label of 'Express Mail "B469249649 Date of deposit August 3, 1993 I hereby certify that this document / right has been deposited in the" Post Office Express Mail to Recipient "Postal Service of the United States under 36 CFR .10 on the date indicated above and addressed to the Director of Patents and Trademarks Washington DC 20231 Anthony D. Sabatelli 34,714 Representative who sends the application Reg. No.
Signed Signature of the Proxy that sends the request Case 4969
COMPOSITIONS FOR PERSONAL CLEANING George End? L Deckner Richard Loren McManus Dawn Marie French
TEQilCO FIELD
The present invention relates to personal cleansing compositions, which clean the skin and deposit an active ingredient on the skin during the cleaning process. These cleaning compositions are in the form of oil-in-water emulsions. These compositions are useful for delivering a wide variety of active ingredients. Cleaning compositions containing salicylic acid as the active ingredient are highly preferred and are useful for cleansing the skin and for providing anti-acne and anti wrinkle benefits of the skin.
Waif iaíM? Ss PE I? IMVEM IOH
There is a continuing interest in providing consumers with personal cleansing compositions, which not only cleanse the skin, but also provide additional skin care benefits. For example, it should be very advantageous to provide products which cleanse the skin completely, and which also deposit various active ingredients on the surface of the skin.
during the cleaning procedure. These dual objectives of cleansing the skin and depositing an active ingredient are difficult to achieve from a single product, since the surfactant ingredients typically found in a skin cleansing product tend to inhibit the deposition of active ingredients. , and also tend to eliminate the active products that have been deposited. Therefore, there is a need to develop compositions which effectively achieve both of these cleaning and deposit objectives. A significant portion of the population suffers from acne. These individuals have special skin cleansing needs. Acne patients need to cleanse their skin to remove dirt, oils, bacteria and other foreign materials. Acne patients also need to treat their skin with various medications to alleviate existing acne lesions and to prevent future acne injuries. Even though cleaning products which contain various active ingredients are known, and which are targeted for those suffering from acne, many of these cleaning products do not effectively deposit therapeutic levels of the active ingredients on the skin. Therefore, those who suffer from acne, need to use two products separately, namely a cleaning product followed by an anti-acne medication, to obtain effective anti-acne protection.
Not only those who suffer from acne have the unfulfilled need to find products that cleanse and treat the skin. For example, a significant portion of the population is related to the effects of skin aging, ie, wrinkle formation, skin hanging, age spots and other skin changes related to age. These individuals also have special needs for cleansing the skin. These individuals need to keep their skin clean and also need to treat their skin to reduce the effects of aging, which have already occurred and to prevent and lessen the presentation of effects of future aging. In addition, these individuals also have the need to moisten their skin. As with acne patients, again there is a lack of products which clean and treat the skin, thus needing the use of products for the cleaning treatment separately.
A wide variety of active ingredients are currently known to treat various skin conditions. Representative of some active ingredients is salicylic acid. Salicylic acid is a well-known eratolytic agent, which is believed to help eliminate keratin plugs and aid in the skin's exfoliation process. Salicylic acid is further described in C. Huber et al., Arch. Derm. Res. 257, pp. 293-297, 1977). Salicylic acid is known for its anti-acne benefits, and is available in numerous products. See C. Huber et al., Arch. Derm. Res .. 257, pp. 293-297, 1977. Salicylic acid is known for its anti-aging skin benefits. See PCT Patent Application No. 9310755 to Blank et al., Published June 10, 1993 and Blank PCT Application No. 9310756, published June 10, 1993. However, it is difficult to provide effective acid levels. salicylic acid to the skin from conventional skin cleansing products. This stimulus is especially difficult in view of FDA regulations, which limit the level of salicylic acid in skin care products to only 2%. See "Topical Acne Drug Products For Over The Counter Human Use Final Monograph", 21 CFR 333, August 16, 1991. Thus, there is a need to develop products which completely cleans the skin and which also provide therapeutically effective levels of acid salicylic to the skin within the restrictions of the FDA formulation.
It has been found in the present invention that cleaning compositions in the form of emulsions, oil in water, can be formulated, which are useful for cleaning the skin and depositing effective levels of a wide variety of active ingredients during the cleaning process. It has been found that emulsions are useful for depositing active materials having a solubility parameter of about 7 to about 13. It has also been found that these emulsions are especially useful for depositing salicylic acid.
It is an object of the present invention to provide oil-in-water emulsion compositions for personal cleansing, which are useful for cleansing the skin and depositing the active ingredients on the surface of the skin during the cleaning process.
It is another object of the present invention to provide compositions which are useful for cleansing the skin and providing an anti-acne benefit.
It is another object of the present invention to provide compositions which are useful for cleansing the skin and providing an anti-aging benefit of the skin.
It is another object of the present invention to provide compositions which are useful for cleansing the skin and for depositing salicylic acid on the surface of the skin during the cleaning process.
It is another object of the present invention to provide methods for cleaning the skin and for depositing active ingredients on the surface of the skin.
These and other objects of this invention will become apparent in the light of the following description.
BRIEF DESCRIPTION OF THE INVENTION
The present invention relates to an oil-in-water emulsion for personal cleansing, comprising: (a) from about 0.05% to about 20% of an active ingredient, having a solubility parameter of from about 7 to about 13; (b) from about 0.1% to about 25% of an alkoxylated ether of the formula
wherein R is selected from the group consisting of H and C- alkyl; .30 of straight chain or branched chain, m is an integer from 0 to about 6, R 'is selected from the group consisting of methyl and ethyl and n is an integer from about 3 to about 30; or an alkoxylated diether of the formula
H (OCHjCH) qO- CH; CH2 p • Cr2 • 0 (HCH20) rH V wherein R "is selected from the group consisting of methyl and ethyl, p is an integer from about 1 to about 6 and each qyr is independently selected such that the sum is an integer from about 3 to about 30; (c) from about 0.05% to about 10% of an emulsifier; (d) from about 0% to about 10% of an auxiliary polymer for deposition; (e) from 0% to about 10% of a polymeric thickener; and (f) from about 25% to about 99.7% water. In another embodiment, the present invention relates to an oil-in-water emulsion composition useful for personal cleansing, comprising: (a) from about 0.05% to about 20% salicylic acid; (b) from about 0.1% to about 25% of an alkoxylated ether of the formula
wherein R is selected from the group consisting of H and a straight chain or branched chain C-, .30 alkyl, m is an integer from 0 to 6,
R 'is selected from the group consisting of methyl and ethyl, and n is an integer from about 3 to about 30; or alkoxylated diether of the formula
H (0CH2CH) q0- CH2 - jcH2jp - CH * - OHHCHÍO
wherein R "is selected from the group consisting of methyl and ethyl, p is an integer from about 1 to about 6 and each q and r are independently selected, such that their sum is an integer from about 3 to about 30, (c) from about 0.05% to about 10% of an emulsifier, (d) from about 0% to about 10% of a deposition aid polymer, (e) from 0% to about 10% of a polymeric thickener and (f) from about 25% to about 99.7% water, wherein the composition has a pH of about 2 to about 7.
In still another embodiment, the present invention relates to an oil-in-water emulsion composition, useful for personal cleansing, comprising: (a) from about 0.05% to about 20% of an active ingredient having a solubility parameter of about 7 to about 13; (b) from about 0.1% to about 25% of an alkoxylated ether of the formula
wherein R is selected from the group consisting of H and C- alkyl; Linear chain or branched chain, is an integer from 0 to about 6, R 'is selected from the group consisting of methyl and ethyl and n is an integer from about 3 to about 30; or an alkoxylated diether of the formula
H (0CH2CH) q0- CH2 - jcH2] p - CH2 - (XfHCH
wherein R "is selected from the group consisting of methyl and ethyl, p is an integer from about 1 to about 6 and each qyr is independently selected, such that its sum is an integer from about 3 to about 30 (c) from about 0.05% to about 10% of an emulsifier; (d) from about 0.1% to about 10% of a deposition auxiliary polymer, which is a mixture of a hydroxy-terminated urethane polymer and a propylene glycol , wherein the weight / weight ratio of the hydroxy-terminated urethane polymer to the polypropylene glycol is from about 1: 1.5 to about 1.5: 1; (e) from 0% to about 10% of a polymeric thickener, and (f) from approximately 25% to approximately 99.7% water All percentages and ratios used herein are by weight of the total composition and all measurements made are at 25 ° C, unless otherwise designated. invention may comprise, or consist of, essential ingredients, as well as optional ingredients and components described herein.
DESCRIPTION PfiTftTiT-APft PE tA INVENCIC-N
The emulsion compositions of the present invention are useful for cleaning the skin and for depositing an active ingredient on the skin during the cleaning process. These compositions are in the form of oil-in-water emulsions, whereby the oily phase and the aqueous phase may contain, in addition to the essential components described herein, a wide variety of ingredients known in the art. The active ingredients are deposited on the skin of the oil phase in the oil-in-water emulsion. The active ingredients for use herein, therefore, will have a solubility parameter of about 7 to about 13. These emulsions are normally used with water to clean the skin. When rinsing with water, these compositions are removed from the surface of the skin along with the soil, oils, bacteria and other foreign material, associated and leave the active ingredients deposited on the skin. The oil-in-water emulsions of the present have advantageous aesthetic properties such as an exquisite and creamy skin feel, not yet greasy. These emulsions can range in a wide consistency from light lotions to heavy creams. These emulsions typically have viscosities in the range of about 100 cps to about 500,000 cps, more preferably from about 1000 cps to about 150,000 cps, and most preferably from about 5,000 cps to about 100,000 cps. The emulsion compositions herein can be extended over a wide range of pH values which can be acidic, basic or neutral depending on the active material or particular active materials used. For example, for acidic active materials, the pH of the composition should be chosen carefully such that it is at or below the pKa of the active ingredient. By standard definitions, the pKa value for a compound is that pH value at which the material is 50 percent dissociated or ionized to produce its conjugate base and a proton (or hydrated proton). Without being limited to any theory when the pH of the formulation is below the pKa of the active ingredient, it is believed that the active ingredient will exist mainly in its un-ionized form, which should increase its subsequent deposit on the skin.
For example, salicylic acid has a pKa that reports 2.97 to 19 ° C in aqueous solution. Therefore, it would be useful to formulate compositions containing salicylic acid at or below a pH of about 2.97 to eliminate ionization and maximize the deposition of the emulsion. See
CRC HandbQQk of Chercistry and Phvsics, 57 Edition, page D-150 (1976). For compositions containing salicylic acid it should be from about 2 to about 7, more preferably from about 2.5 to about 5, still more preferably from about 2.5 to about 4, and most preferably from about 2.5 to about 3. Even when the buffers can be used to help maintain the pH of the emulsion compositions, these components are not required but are only optional.
(a) ACTIVE GLOBAL
The emulsion compositions of the present invention comprise a safe and effective amount of an active ingredient, which is deposited on the surface of the skin during the cleaning process. These emulsions can. contain a mixture of two or more active ingredients. By the term "safe and effective amount" as used herein, it means an amount of an active ingredient sufficiently high to modify the condition to be treated or to provide the benefit of the desired skin, but low enough to avoid serious side effects in a reasonable ratio of benefit to risk within the scope of medical judgment. What is a safe and effective amount of the active ingredient, will vary with the specific active ingredient, the ability of the active ingredient to penetrate through the skin, the age, the state of health and condition of the user's skin and other similar factors . Normally, the active ingredients of the present invention, consist of from about 0.05% to about 20%, more preferably from about 0.1% to about 10% and most preferably from about 1% to about 5%. The active ingredients useful herein have a solubility parameter of from about 7 to about 13, preferably from about 7.5 to about 12.5 and most preferably from about 8 to about 12. The solubility parameters are well known to the formulations with ordinary skill in the art and are routinely used as a guide to determine the compatibilities and solubilities of materials in the formulation process. Without being limited by theory, it is believed that in the choice of active materials with solubility parameters in the ranges designated in the foregoing, that the active ingredients will tend to be hydrophobic, i.e., lipophilic, and therefore more soluble in water. the oil phase of the oil-in-water emulsions of the present invention. The lipophilic nature of the active ingredients should help to increase the deposition of the active ingredient on the skin of an oil-in-water emulsion by rinsing the emulsion with water. Generally, the active ingredients useful herein, will have a solubility in water at 25 ° C of at least about 1 gram per about 100 grams of water. The solubility parameter of a chemical compound, d, is defined as the square root of the density of the cohesive energy for this compound. Normally, a solubility parameter for a compound is calculated from the tabulated values of the additive group contributions for the heat of vaporization and molar volume of the components of that compound, using the following equation:
where i2 E¿ = the sum of the heat of vaporization of the contribution of the additive group. is m = the sum of the molar volume of the contributions of the additive group. Standard tabulations of the heat of vaporization and molar volume of the contributions of the additive group to a wide variety of atoms and groups of atoms are collected in Barton, A.F..M. Handbook of Solubility Parameters. CRC Press, Chapter 6, Table 3, pp. 64-66 (1985), which is incorporated herein by reference in its entirety. The solubility parameters of the equation are described in Fedors, R.F., "A Method for Estimating Both the Solubility Parameters and Molar Volumes of Liquids", Polvmer Enaineerina and Science. vol. 14, no. 2, pp.
147-154 (February 1974), which is incorporated herein by reference in its entirety. The calculated solubility parameters obey the laws of the mixtures, in such a way that the calculated solubility parameter for a mixture of materials is given by the heavy average of the solubility parameters calculated for each component of that mixture, see. Handbook of Chemistry and Physics. 57th Edition, CRC Press, p. C-726 (1976-1977), which is incorporated herein by reference in its entirety. In the formulation, they normally report and use the solubility parameters in units of (cal / crrr) ''. The tabulated values of the contributions of the additive group for the heat of vaporization in Handbook of Solubilitv Parameters are reported in units of kJ / mol. However, these tabulated vaporization heat values are easily converted to cal / mol using the following well-known relationships:
1 J / mol = 0.239006 cal / mol and 1000 J = 1 kJ.
ease Gordon, A.J.- et al., The Chemist 's Companion. John Wiley & Sons, pp. 456-463, (1972), which is incorporated herein by reference in its entirety. The solubility parameters can be tabulated for a wide variety of chemical compounds. Fablers of solubility parameters are found in Handbgok gf SolubilitY Parameters »The active ingredients useful herein can be classified by their therapeutic benefit or their postulated form of action. However, it should be understood that the active ingredients useful herein may, in some cases, provide more than one therapeutic benefit or function by means of one or more means of action. Therefore, any of the classifications herein are made for the purpose of convenience are not intended to limit the active ingredient for that particular application or applications listed. Among the classes of active ingredients useful herein, based on therapeutic benefit or mode of action, are the following. Anti-acne active ingredients: Examples of anti-acne active ingredients include keratolytics, such as salicylic acid and resorcinol; retinoids such as retinoic acid and its derivatives (e.g., cis and trans); antibiotics and antimicriobials such as benzoyl peroxide, octopirox, erythromycin and its metal complexes (eg, zinc erythromycin), tetracycline, 2,4,4'-trichloro-2'-hydroxydiphenylether, 3,4,4'-trichlorobanilide, azelaic acid and its derivatives, phenoxyethanol, phenoxypropanol, phenoxyisopropanol, ethyl acetate, clindamycin and eclocycline; cebostatic agents such as flavinoids; alpha and beta hydroxy acids and bile salts such as escimnol sulfate and its derivatives, deoxycholate and cholate. Anti-wrinkle and anti-atrophy active ingredients of the skin: Examples of anti-wrinkle and anti-atrophy active ingredients of the skin include retinoic acid, salicylic acid and skin release agents (e.g., phenol and the like) . Non-steroidal anti-inflammatory active ingredients (NSAIDs): Examples of NSAIDs include the following categories: propionic acid derivatives; acetic acid derivatives; phenamic acid derivatives; biphenylcarboxylic acid derivatives and oxicams. All of these NSAIDs are fully described in U.S. Patent 4,985,459 to Sunshine et al., Issued January 15, 1991, incorporated herein by reference. Examples of useful NSAIDs include acetylsalicylic acid, acetaminophen, ibuprofen, naprofen, benoxaprofen, flurbiprofen, fenoprofen, fenbufen, ketoprofen, indoprofen, pirprofen, carprofen, oxaprozin, pranoprofen, miroprofen, thioxaprofen, suprofen, alminoprofen, thiaprofenic acid, fluprofen and bucilloxic acid. Also useful are steroidal, anti-inflammatory drugs including hydrocortisone and the like. Topical Anesthetics: Examples of topical anesthetic drugs include lidocaine, bupivacaine, chloroprocaine, dibucaine, etidocaine, epivacaine, tetracaine, dyclonine, hexylcaine, procaine, cocaine, ketamine, pramoxin, phenol and their pharmaceutically acceptable salts. Antimicrobial and antifungal active ingredients: Examples of antimicrobial and antifungal active ingredients include ß-lactam drugs, quinolone drugs, ciprofloxacin, norfloxacin, tetracycline, erythromycin, amiccation, 2,4,4'-trichloro-2-hydroxy diphenylether, 3, 4,4'-trichlorobanilide, phenoxyethanol, phenoxypropanol, phenoxyisopropanol, doxycycline, capreomycin, chlorhexidine, chlortetracycline, oxytetracycline, clindamycin, ethambutol, hexamidine isethionate, metronidazole, penta idine, gentamicin, kanamycin, lineomycin, metacycline, methenamine, minocycline, neomycin, methylmycin, paromomycin, streptomycin, trobamycin, miconazole, tetracycline hydrochloride, erythromycin, zinc erythromycin, erythromycin estolate, erythromycin stearate, amikacin sulfate, doxycycline hydrochloride, capreomycin sulfate, chlorhexidine gluconate, chlorhexidine hydrochloride, hydrochloride Chlortetracycline, oxytetracycline hydrochloride, hydrochloride indamicin, ethambutol hydrochloride, metronidazole hydrochloride, pentamidine hydrochloride, gentamicin sulfate, lineomycin hydrochloride, metacycline hydrochloride, methenamine hippurate, methenamine mandelate, minocycline hydrochloride, neomycin sulfate, netilmicin sulfate, parmozin sulfate, streptomycin sulfate, tobramycin sulfate, miconazole hydrochloride, amanfadine hydrochloride, amanfadine sulfate, octopirox, parachloromethaxyleneol, nystatin, tolnaftate and clotri azole. Sunscreen agents: A wide variety of active sunscreening ingredients are useful herein and include those described in US Patent No. 5,087,445 to Haffey et al., Issued February 11, 1992.;
U.S. Patent No. 5,073,372, Turner et al., Issued December 17, 1991; U.S. Patent No. 5,073,371, Turner et al., Issued December 17, 1991; and Segarin, et al., in Chapter VIII, pages 189 et seq., of Cos eticg Science nd TechUQlQg ?. all of which are incorporated herein by reference in their entirety. Non-limiting examples of active ingredients for sun protection include those selected from the group consisting of 2-ethylhexyl p-methoxycinnamate, 2-ethylhexyl N, N-dimethyl-p-aminobenzoate, p-aminobenzoic acid, 2-phenylbenzimidazole acid. Sulfonic acid, octocrylene, oxybenzone, homomenthyl salicylate, octyl salicylate, 4,4'-methoxy-i-butyldibenzoylmethane, 4-isopropyldibenzoylmethane, 3-benzyldencafor, 3- (4-ethylbenzylidene) camphor, and mixtures thereof. Still other useful sunscreens are those described in U.S. Patent No. 4,937,370 to Sabatelli, issued June 26, 1990; and U.S. Patent No. 4,999,186 to Sabatelli et al., issued March 12, 1991; These two references are incorporated herein by reference in their entirety. The sun protection agents described herein have, in a single molecule, two different chromophore portions which have different spectra of absorption of ultraviolet radiation. One of the chromophore portions absorbs predominantly in the UV radiation range and the other absorbs strongly in the UVA radiation range. These agents for sun protection provide superior efficacy, wider UV absorption, lower skin penetration and long-lasting efficacy relative to conventional sunscreens. Especially preferred examples of these sunscreens include those selected from the group consisting of 4-N, N- (2-ethylhexyl) methylaminobenzoic acid, 2,4-dihydroxybenzophenone ester, 4-N, N- ( 2-ethylhexyl) methylaminobenzoic acid, ester with 4-hydroxydibenzoylmethane, 4-N, N- (2-etxl-hexyl) methylaminobenzoic acid, ester of 2-hydroxy-4- (2-hydroxyethoxy) benzophenone, acid 4,, N- (2-ethylhexyl) -methylaminobenzoic acid ester of 4- (2-hydroxyethoxy) -dibenzoylmethane and their mixtures. Preferred examples of active ingredients useful herein include those selected from the group consisting of salicylic acid, 3-hydroxybenzoic acid, 4-hydroxybenzoic acid, acetylsalicylic acid, 2-hydroxybutanoic acid, 2-hydroxypentanoic acid, 2-hydroxyhexanoic acid, cis-retinoic acid, trans-retinoic acid, azelaic acid, arachidonic acid, benzoyl peroxide, tetracycline, ibuprofen, naproxen, hydrocortisone, acetaminophen, erythromycin, zinc erythromycin, resorcinol, phenoxyethanol, phenoxypropanol, phenoxyisopropanol, 2,4,4 '- trichloro-2'-hydroxydiphenylether, 3,4,4'-trichlorocarbanilide, octopirox, lidocaine hydrochloride, clotrimazole, miconazole, neocin sulfate, 2-ethylehexyl p-methoxycinnamate, N, N-dimethyl-p-aminobenzoate 2- ethylhexyl, p-aminobenzoic acid, 2-phenylbenzimidazole-5-sulfonic acid, octocrylene, oxybenzone, homomenthyl salicylate, octyl salicylate, 4,4'-methoxy-i-butyl-dibenzoylmethane , 4-isopropyl-dibenzoylmethane, 3- benzylidenecamphor, 3- (4-methylbenzylidene) camphor, 4- N, N- (2-ethylhexyl) -methylaminobenzoic acid, 2,4-dihydroxybenzophenone ester, 4, N, N - (2-ethylhexyl) methylaminobenzoic acid with 4-hydroxydibenzoylmethane, 4-N, N- (2-ethylhexyl) methylaminobenzoic acid, 2-hydroxy-4- (2-hydroxyethoxy) benzophenone ester, 4, N, N, N- (2-ethylhexyl) -methyl-isobenzoic acid 4- (2-hydroxyethoxy) dibenzoylmethane and mixtures thereof. More preferred examples of the active ingredients useful herein, include those selected from the group consisting of salicylic acid, acetylsalicylic acid, cis-retinoic acid, trans-retinoic acid, azelaic acid, tetracycline, ibuprofen, naproxen, acetaminophen, hydrocortisone, erythromycin, zinc erythromycin, resorcinol, phenoxyethanol, phenoxypropanol, phenoxy-isopropanol, 2,4,4'-trichloro-2'-hydroxy diphenyl ether, 3,4,4'-trichlorocarbanilidia, octopirox, p-methoxycinnamate of 3-ethylhexyl, 2-ethylhexyl n-N-dimethyl-p-aminobenzoate, 2-phenylbenzimidazole-5-sulfonice acid, octocrylene, oxybenzone, homomenthyl salicylate, octyl salicylate, 4,4'-methoxy-butyl-benzyl - zoylmethane, 4-isopropyldibenzoylmethane, 3-benzylidenecamphor, 3- (4-methylbenzylidene) camphor, 4, N, N- (2-ethylhexyl) -methylaminobenzoic acid ester with 4- (2-hydroxy-ethoxy) dibenzoylmethane and its mixtures More preferred examples of the ingredients useful herein include those selected from the group consisting of salicylic acid, cis-retinoic acid, trans-retinoic acid, azelaic acid, erythromycin, resorcinol, ibuprofen, naproxen, hydrocortisone, phenoxyethanol, phenoxypropanol , phenoxyisopropanol, 2,4,4'-trichloro-2'-hydroxy diphenyl ether, 3,4,4'-trichlorocarbanilide, 2-ethylhexyl p-methoxycinnamate, N, N-dimethyl-p-aminobenzoate 2- ethylhyexyl, 2-phenylbenzimidazole-5-sulfonic acid, octocrylene, oxybenzone, homomenthyl salicylate, octyl salicylate, 4,4'-methoxy-i.-butyldibenzoyl ethane, 4-isopropyldibenzoylmethane, 3-benzylidenecamphor, 3- (4-methylbenzylidene) ) camphor, 4- (2-hydroxyethoxy) dibenzoylmethane ester and its mixtures 4, N- (2-ethylhexylmethylaminobenzoic ester) A salicylic acid is a particularly useful active ingredient here.
(fr) ÉTERES Y PIETERES MiTOXI ftDQS
The compositions of the present invention comprise from about 0.1% to about 25%, preferably from about 0.1% to about 15% and more preferably from about 6% to about 10% of an alkoxylated ether, which is useful for solubilizing the active ingredients in the oil phase of oil-in-water emulsions. The alkoxylated ethers and diethers useful herein generally have a solubility in water of less than about 1 gram per about 100 grams of water at 25 ° C. These compounds are typically formulated in the oil phase of the oil-in-water emulsions as described in the following Examples. The mixtures of alkoxylated ethers and diethers can be used herein. The alkoxylated ethers useful herein can be described by the following general formula
R - TCH - CH2 - 0 < fHCH2?) rtH
wherein R is selected from the group consisting of H and C 1-30 alkyl, straight chain or branched chain, m is an integer from 0 to about 6, R 1 is selected from the group consisting of methyl and ethyl, and is an integer from about 3 to about 30. Preferably R is selected from the group consisting of straight or branched chain C2-25 alkyl, m is an integer from 0 to about 2, R 'is methyl and n is an integer from about 5 to about 25. Most preferably R is selected from the group consisting of C2-20 alkyl, straight or branched chain, is an integer from 0 to about 1, R 'is methyl and n is a number whole from about 10 to about 20.
Non-limiting examples of the classes of alkoxylated ethers useful herein include propoxylated and butoxylated ethers of alcohols and polyols. These compounds can be described as PPG and PGB alkyl ethers, in which PPG and PBG are the designations commonly used for propylene glycol. and polybutylene glycol, respectively. The average number of PPG or PBG groups in these ethers is commonly given by a designation number after PPG or PBG. For example, PPG-14 butyl ether, would designate a butanol propylene glycol ether, in which the molecule has an average of 14 propylene glycol units. Non-limiting examples of alkoxylated ethers useful herein include PPG-10 butyl ether, PPG-11 butyl ether, PPG-12, butyl ether, PPG-13 butyl ether, PPG-14-butyl ether, PPG-15 butyl ether, PPG-15 butyl ether, PPG- 17 butyl ether, PPG-18 butyl ether, PPG-19 butyl ether, PPG-20 butyl ether, PPG-22 butyl ether, PPG-24 butyl ether, PPG-30 butyl ether, PPG-11 stearyl ether, PPG-15 stearyl ether, PPG-10 oleyl ether, PPG- 7 lauryl ether, PPG-30 isocetyl ether, PPG-10 glyceryl ether, PPG-15 glyceryl ether, PPG-10 butylene glycol ether, PPG-15 butylene glycol, PPG-27 glyceryl ether, PPG-30 cetyl ether, PPG-28 cetyl ether, PPG-10 cetyl ether, PPG- Hexylene glycol ether, PPG-15 hexylene glycol ether, PPG-10, 1,2,6-hexanetriol ether, PPG-15, 1, 2,6-hexanetriol ether and mixtures thereof. Preferred alkoxylated ethers are those selected from the group consisting of PPG-14 butyl ether, PPG-15 stearyl ether, PPG-11 stearyl ether,
PPG-20 oleyl ether and its mixtures. Preferred alkoxylated ethers are those selected from the group consisting of PPG-14 butyl ether, PPG-15 stearyl ether, and mixtures thereof. PPG-14 butyl ether is available under the trade name Fluid AP from the Union Carbide Corporation. PPG-15 stearyl ether is available under the trade name Arla ol E from ICI Americas Corporation. Alkoxylated diethers are also useful herein. These compounds can be represented by the general formula:
H (OCH2fH) qO- CH2. [cH2] p - CH2 - OffHCHtf
wherein each R "is selected from the group consisting of methyl and ethyl, p is an integer from about 1 to about 6, and each qyr is independently selected such that sum is an integer from about 3 to about 30. Preferential R "is methyl, p is an integer from about 2 to about 4 and qyr are independently selected, such that their sum is an integer from about 5 to about 25. Most preferably R "is methyl, p is an integer of about 2. to about 4, and each qyr are independently selected such that their sum is an integer of from about 10 to about 20. Non-limiting examples of the alkoxylated diethers useful herein include those selected from the group consisting of PPG-10. 1,4-butanediol ether, PPG-12 1,4-butanediol ether, PPG-14 1,4-butanediol ether, PPG-2 butanediol ether, PPG-10 1,6-hexanediol ether, PPG-12 1,6-hexanediol ether, PPG- Hexanodioldiethher, PPG-20 hexanedioldiethier, and mixtures thereof Preferred are those selected from the group consisting of PPG-10 1,4-butanedioliether, PPG-.12 1,4-butanedioliether, PPG-10 1,6-hexanedioldiieter, and PPG-12 h exanodioldiéter, and their mixtures. The most preferred is PPG-10 1,4-butanediol ether. This compound is commercially available under the tradename Macol 57 from PPG / Mazer Corporation.
(C) BMüLSIgIGftPQR
The compositions of the present invention, consist of from about 0.1% to about 10%, preferably from about 0.2% to about 5% and more preferably from about 0.25% to about 2.5% of at least one emulsifier. The emulsifier is used herein to emulsify the ingredients of the oil and water phase and to stabilize the resulting emulsion. Although the term "emulsifier" is used herein to describe these materials, this term is not intended to exclude those emulsifiers which also have surfactant properties. Emulsifiers useful herein may include any of a wide variety of nonionic, cationic, anionic and zwitterionic emulsifiers described in the above patents and other references. See McCutcheon's, Detergents and Emulsifieres. North American Edition (1986), published by Allured Publishing Corporation; U.S. Patent No. 5,011,681 to Ciotti et al., Issued April 30, 1991; U.S. Patent No. 4,421,769 to Dixon et al., issued December 20, 1983; and U.S. Patent No. 3,755,560 to Dickert et al., issued August 28, 1973; These four references are incorporated herein by reference in their entirety. The exact emulsifier chosen will depend on the pH of the composition and the other components present. Suitable types of emulsifiers include tetraalkylammonium salts, glycerin esters, 4-propylene glycol esters, polyethylene glycol fatty acid esters, propylene glycol fatty acid esters, sorbitol esters, sorbitan anhydride esters, carboxylic acid copolymers, esters and glucose ethers, ethoxylated ethers, ethoxylated alcohols, algayl phosphates, polyoxyethylene fatty acid phosphates, fatty acid amides, acyl lactylates, soaps and mixtures thereof. Preferred herein, especially when the emulsions have a pH of about 2 to about 7, are cationic emulsifiers. A wide variety of cationic emulsifiers and surfactants useful herein are described in U.S. Patent No. 5,151,209 to McCall et al., Issued September 29, 1992; U.S. Patent No. 5,151,210 to Steuri et al., issued September 29, 1992; U.S. Patent No. 5,120,532 to Wells et al., issued June 9, 1992; U.S. Patent No. 4,387,090, issued by Bolich, June 7, 1983; U.S. Patent No. 3,155,591, Hlfer, issued November 3, 1964; U.S. Patent No. 3,929,678 to Laughlin et al., issued December 30, 1975; U.S. Patent No. 3,929,461 to Bailey et al., issued May 25, 1976; MeCuteheon 's. Deteraents &
Emulsifiers (North American Edition 1979) M.C. Publishing Co.; and Schwartz, et al., Surface Active en es, Their Chemistrv d Te hndQCY, New York:
Interscience Publishers, 1949; All documents are incorporated herein by reference in their entirety. Cationic emulsifiers useful herein include cationic ammonium salts such as those having the formula:
where R- | , is selected from an alkyl group having from about 12 to about 22 carbon atoms, or aromatic, aryl or alkaryl groups, having from about 12 to about 22 carbon atoms; R2"R3 and R4 are independently selected from hydrogen, an alkyl group having from about 1 to about 22 carbon atoms, or aromatic, aryl or alkaryl groups, having from about 12 to about 22 carbon atoms; and X is an anion selected from chloride, bromide, iodide, acetate, phosphate, nitrate, sulfate, methyl sulfate, ethyl sulfate, tosylate, lactate, citrate, glycolate and mixtures thereof. Additionally, the alkyl groups may also contain ether linkages or substituents hydroxy group or amino group (eg, alkyl groups, ethylene glycol and polypropylene glycol portions) Most preferably, R- | is an alkyl group having from about 12 to about 22 -atoms of carbon, R2 is selected from H or an alkyl group having from about 1 to about 22 carbon atoms; R3 and R4 is independently selected from H or an alkyl group having from about 1 to about 3 carbon atoms; and X is as described in the previous paragraph.
More preferably, R- | is an alkyl group having from about 12 to about 22 carbon atoms; R2, R3 and R4 are selected from H or an alkyl group having from about 1 to about 3 carbon atoms; and X is as previously described. Alternatively, other useful cationic emulsifiers include amino-amides, wherein the structure R- | above is alternatively R5CO- (Chin in which R5 is an alkyl group having from about 12 to about 22 carbon atoms, and n is an integer from about 2 to about 6, more preferably from about 2 to about 4 and greater preferably from about 2 to about 3. Non-limiting examples of these cationic emulsifiers include stearoamidopropyl PG-diammonium phosphate chloride, stearoamidopropylethylimoniate ethanesulfate, stearamidopropyl dimethyl (myristyl acetate) ammonium chloride, stearamidopropyl dimethyltenetethylammonium tosylate, stearamidopropyl dimethyl ammonium chloride, stearamidopropyl dimethyl ammonium lactate and their mixtures Non-limiting examples of the cationic emulsifiers of the quaternary ammonium salt include those selected from the group consisting of cetylammonium chloride, cetyl onium bromide, laurylammonium chloride, laurylammonium bromide, stearylamide chloride nium, stearylammonium bromide, cetyl dimethyl ammonium chloride, cetyl diimethylammonium bromide, lauryl dimethyl ammonium chloride, lauryl dimethyl ammonium bromide, stearyldimethylammonium chloride, stearyldimethylammonium bromide, cetyltrimethylammonium chloride, cetyltrimethylammonium bromide, lauryltrimethylammonium chloride, lauryltrimethylammonium bromide, steariltrimium chloride - tilamonium, stearyltrimethylammonium bromide, lauryldimethylammonium chloride, stearyldimethyl-cetilditalow dimethylammonium chloride, dicetyl ammonium chloride, di-ethyl ammonium bromide, dilaurammonium chloride, diolaurylammonium bromide, distearylammonium chloride, distethylammonium bromide, dicetylmethylammonium chloride, dicetylmethylammonium chloride, dicetylmethylammonium bromide, dilaurylmethylammonium chloride, dilaurylmethylammonium bromide, methylammonium chloride, distearylmethylammonium bromide and mixtures thereof. Additional quaternary ammonium salts include those in which the C12 to C22 alkyl carbon chain is derived from a fatty acid of bait or of a coconut fatty acid. The term "bait" refers to an alkyl group derived from bait fatty acids (usually hydrogenated bait fatty acids), which generally have mixtures of alkyl chains in the range of C16 to C18. The term "coconut" refers to an alguyl group derived from a coconut fatty acid, which generally has mixtures of alkyl chains in the range of C12 to C14. Examples of quaternary ammonium salts, derived from these bait and coconut sources, include dikebo-dimethylammonium chloride, dikebo-dimethylammoniomethyl sulfate, di (hydrogenated bait) dimethylammonium chloride, di (hydrogenated bait) dimethylammonium acetate, dike phosphate - dipropylammonium, dikebo-dimethylammonium citrate, di (coconut alkyl) dimethylammonium chloride, di (coconut alkyl) dimethylammonium bromide, cebammonium chloride, cocoammonium chloride, stearamidopropyl PG-dimonium chloride phosphate, ethanolamidopropylethylimoniate ethoxide , Stearic Rampropyl Dimethyl (Ammonium Myristyl Acetate, Stearamidopropyldimethyltearylammonium Tosylate, Stearamidopropyldimethylammonium Chloride, Stearamidopropyldimethylammonium Lactate, and Their Mixtures The most preferred cationic emulsifiers are those selected from the group consisting of dilauryldimethylammonium chloride, distearyldimethylammonium chloride, dimyristyl dimethyl ammonium chloride , dipalmityldimethylammonium chloride, distearyldimethylammonium chloride, stearamidolpropyl PG-dimonium chloride phosphate, stearamidopropylethylimoniate ethosulfatestearamidepropyl (myristyl acetate) ammonium chloride, stearamidopropyl dimethyltearylammonium tosylate, stearamidopropyldimethylammonium chloride, stearamidopropyldimethylammonium lactate and mixtures thereof. The most preferred cationic emulsifiers are those selected from the group consisting of dilauryl dimethyl ammonium chloride, distearyldimethylammonium chloride, dimyristyldimethylammonium chloride, dipalmityldimethylammonium chloride, distearyldimethylammonium chloride, and mixtures thereof.
(d) POLYMER TO HELP THE DEPOSIT
The compositions of the present invention consist of from 0.1% to about 10%, preferably from about 0.1% to about 10%, more preferably from about 0.25% to about 7.55 and most preferably from about 0.50% to about 5% of a polymer to assist the deposit to increase the deposition of the active ingredient on the skin. Without being limited to any theory, the auxiliary polymer of the deposit is believed to aid in the deposition of the active ingredient from the oil phase of the oil-in-water emulsion whereby the active ingredient is deposited on the skin during the cleaning and assistance procedure. the active agent to adhere to the skin during the rinsing procedure. The auxiliary deposition polymers useful herein are typically formulated in the oil phase of the oil-in-water emulsions, as described in the following examples. A variety of polymers to aid deposition are useful herein and include those selected from the group consisting of hydroxy terminated urethane polymers, propylene glycols and mixtures thereof.
It has been ethical. I am interested in the fact that ßß obtains preferred high-mettlß emulsions when the polymer stops __yud__r _üpoßito is __na ßnacla dß a hydroxy-terminated urine polymer and a propylene glycol.
When these two types of deposition-assisting polymers are used in conjunction, the weight / weight ratio of the hydroxy-terminated urethane polymer to the polypropylene glycol polymer is from about 1: 1.5 to about 1.5: 1, preferably from about 1.25: 1 to about 1: 1 .25, more preferably about 1. 1: 1 to approximately 1: 1. 1 and more preferably approximately 1: 1. poTiTmamfí PE VBS ÍBO tBR? au_Dffi. TM G? T ?? T.O__T
The hydroxy-terminated urethane polymers useful as deposit aids herein are those generally described in US Patent No. 5,051,260 to Chess et al., Issued September 24, 1991; U.S. Patent No. 5,045,317 to Chess et al, issued September 3, 1991; and U.S. Patent No. 4,971,800, to Chess et al., issued November 20, 1990; all of which are incorporated herein by reference in their entirety. These hydroxy-terminated urethane compounds are represented by the general formula (it should be understood that this formula represents a linear polymer chain and is illustrated as such, solely by convenience and space restrictions):
O H H 0 H- (0- «l) • O - C - H - - M - C n
O H H g (O-Rl) ß - O • C - N • R • N - - O • (R ^ -O),
wherein R represents an alkyl or alkenyl radical having from about 1 to about 20 carbon atoms or a cycloalkyl or cycloalkenyl radical containing from about 5 to about 10 carbon atoms or a mononuclear or fused aryl ring radical containing about 6 to about 10 carbon atoms, unsubstituted or substituted with one or more C1-C6 alkyl groups, C1-C6 alkoxy, C1-C6 alkoxy, substituted with C1-C6, nitro or amino or halogen atoms; R is the same radical or a different alkyl or alkenyl radical; m is a whole number selected to provide a portion (0-R1) having a molecular weight of from about 40 to about 6000, preferably from about 400 to about 2000; ynyn 'are integers equal or different from 0 to about 30 inclusive, correlated with to provide a hydroxy-terminated urethane compound having a molecular weight of up to about 200,000, preferably from about 220 to about 37,000 and preferably from about 1,000 to about 5000. The hydroxy-terminated urethane compounds are prepared using standard synthetic techniques from the reaction of linear alkylene or polyalkylene glycols or polyethers with monomeric organic diisocyanates. Alkylene or linear polyalkylene glycols or polyethers are represented by the general formula:
H- (0-R1) m-0-H
where R and m are as described in the preceding paragraph. Specific non-limiting examples of the polyalkylene glycol or polyether reagents include: diethylene glycol, triethylene glycol, PEG-4, PEG-6, PEG-8, PEG-9, PEG-10, PEG-12, PEG-14, PEG-16, PEG -18, PEG-20, PEG-32, PEG-40, PPG-9, PPG-12, PPG-15, PPG-17, PPG-20, PPG-26, PPG-30, PPG-34, and polytetramethylene glycols they have molecular weights in the range of about 600 to 6000 similar. The terms "PEG" and "PPG" are the CTFA designations commonly used for polyethylene glycol and polypropylene glycol, respectively. The number after the designation indicates the average number of units of ethylene glycol or polypropylene glycol in the molecule. Also, the polyalkylene glycols or polyether mixtures described above may also be employed to prepare the hydroxy-terminated urethanes useful herein. The monomeric organic diisocyanates are represented by the general formula:
O = C = N-R-N = C = 0
wherein R is an alkyl or alkenyl radical having from about one to about 20 carbon atoms or a cycloalkyl or cycloalkenyl radical containing from about 5 to about 10 carbon atoms or a mononuclear or fused ring aryl radical containing about 6 to about 10 carbon atoms, unsubstituted or substituted with one or more C1-C6 alkyl groups, C1-C6 alkoxy, Cl-C6 alkoxy substituted with C1-C6, nitro or amino or halogen atoms. Non-limiting examples of the diisocyanates are aromatic diisocyanates, such as m-phenylene diisocyanate, p-phenylene diisocyanate, 4-t-butyl-m-phenylene diisocyanate, 4-methoxy-m-phenylene diisocyanate, 4-phenoxy-m-phenylene diisocyanate, 4-chloro -m-phenylene diisocyanate, toluene diisocyanates (either as a mixture of isomers, for example, the commercially available mixture of 80% 2,4-toluene diisocyanate and 20% 2,6-toluene diisocyanate, or as individual isomers per se), m-xylidenediisocyanate, p-xylylene diisocyanate, cumen-2,4-diisocyanate, durendiisocyanate, 1,4-naphthylidene diisocyanate, 1,5-naphthylene diisocyanate, 1,8-naphthylidene diisocyanate, 2,6-naphthylene diisocyanate, 1,5-tetrahydronothylene diisocyanate, P, p'-diphenyldiisocyanate, diphenylmethane-4,4'-diisocyanate, 2,4-diphenylhexan-1,6-diisocyanate, "bitolenediisocyanate" (3,3'-dimethyl-4,4'-biphenylene diisocyanate), " dianisidin-ediisocyanate "(3,3'-dimethoxy-4,4'-biphenylene diisocyanate); aliphatic diisocyanates such as methylene diisocyanates, ethylene diisocyanate, tri-tetra-, penta-, hexa-, octa-, nona and decamethylene-omega, omega-diisocyanates, 2-chloro-tr? methylene diisocyanate, 2,3-dimethyltetra-ethylene diisocyanate and the like, as also their mixtures. A preferred hydroxy-terminated urethane polymer useful herein is poly [oxy (methyl-1,2-ethanediyl)], alpha-hydro-omega-hydroxy-, which forms a polymer with 1, 1'-methylene -bis- (4-isocyanatocyclohexane). This material is also known by the CTFA designations as polyol-prepolymer-2 and is commercially available as Topicare 35A from Penederm Inc. through its distributor Barnet Products Corp. (Englewood Cliffs, NJ).
POLYPROPYLENGLICO ES
The polypropylene glycols are useful as polymers to aid in the deposit. Polypropylene glycols are polymers which are normally formed from the polymerization of propylene oxide, polypropylene glycol, propylchlorohydrin, propylbromohydrin and other related materials. The polypropylene glycols are represented by the following formula:
H (0CH2CH) n0H CH3 wherein n is an integer from about 10 to about 50, preferably wherein n is an integer from about 15 to about 40 and most preferably wherein n is an integer of about 20 to about 34. In the previous structure, even when an isomeric orientation is illustrated for convenience, this illustration is not intended to exclude other isomeric structures. Polypropylene glycols are commonly referred to as PPGs followed by a number that indicates the average number of periodic units in the structure. For example, the PPG-30 would correspond to the above structure, where n has an average value of about 30. Based on this nomenclature, the polypropylene glycols useful herein encompass those designated as PPG-10 to PPG-50, greater preference those designated as PPG-15 to PPG-40, and more preferably those designated as PPG-20 to PPG-34. An especially preferred PPG for use in the compositions herein is PPG-30, which is sold under the trade name Polyglycol P-4000 and is commercially available from Dow Chemical Corporation.
(e) PQLIMERICQ THICKENER
The compositions of the present invention consist of from 0% to about 10%, preferably from about 0.5% to about 5%, and most preferably from about 1% to about 4% of a polymeric thickener. A wide variety of thickeners can be employed herein with the choice depending on the pH of the formulation and the other chosen components of the emulsion. For compositions having a pH of about 2 to about 7, the thickeners should be stable within this pH range, ie, they should not degrade and should not lose their thickening capacity. Preferred thickeners include those selected from the group consisting of crosslinked polyacrylate polymers, alkyl-modified hydroxyalkyl cellulose polymers, quaternary ammonium hydroxyalkyl cellulose polymers and mixtures thereof.
PQLIACRILAMIDE POLYMERS Polyacrylamide polymers useful as thickeners include both cationic and nonionic polymers, cations being generally preferred. Examples of cationic polymers, useful and cross-linked cationic polyacrylate polymers, are those described in US Pat. No. 5,100,660, Hawe et al., Issued on March 31, 1992; US Patent L +, 649, 1 + 6"+, by Heard, issued July 1, 1969; North American Patent 4,635,206, Farrar et al., Issued May 30, 1969; US Patent 4,626,076, Glover et al., issued December 9, 1966, US Patent 4,599,379 to Flesher et al., issued July 6, 1966, and EP 226,666 to Farrar et al., published July 15, 1967, all the These cationic polymers are high molecular weight materials, containing cationic portions, usually quaternized nitrogen, These polymers can be characterized by the general formula: (A); L (B) , n (C) ", wherein (A) is a dialkylaminoalkyl acrylate monomer or its acid addition salt or quaternary ammonium salt (B), is a dialkylaminoalkyl methacrylate monomer or its addition salt of acid or quaternary ammonium salt (C) is a monomer having a carbon-carbon double bond, 1 is an integer of 0 or greater, is an integer of 0 or greater, n is an integer of O or greater. The monomer (C) can be selected from any of the monomers commonly used. Non-limiting examples of these monomers include ethylene, propylene, butylene, isobutylene, eicosene, maleic anhydride, acrylamide, methacrylamide, maleic acid, acrolein, cyclohexene, et vinyl ether, and methovinyl ether. In the cationic polymers of the present invention IC) it is preferably acrylamide. These polymers () (B), n (C),., Also consist of a crosslinking agent, which is more typically a material containing two or more unsaturated functional groups. In other words, these polymers expressly also intend to include the crosslinking agent in addition to the monomer units of (A), (B) and (C). As is well known to one skilled in the art of polymer science, a crosslinking agent is reacted with the monomeric units of the polymer and incorporated into the polymer so that they form links or covalent.es links, between two or more individual polymer chains, or between two or more sections of the same polymer chain. Non-limiting examples of suitable crosslinking agents include those selected from the group consisting of methyl mercapto-lamides, dialkali-lamon halides, polyalkyl polyether polyhydric alcohols, acellum acrylates, vinyloxyalkyl acrylates and polyfunctional vinylidenes. Specific examples of the crosslinking agents useful herein include those selected from the group consisting of methylebis, lipac, and lamimide., di (met) acplato de et i liclicol, di (met) acr? lick, cyanomethyl acllate, vimloxiet lly acrylate, vinyloptalene ethacrylate, allylpentaeptritol, tpmet i lolpropanodiali lter, allylsucrose, butadiene, isoprene, divinylbenzene, divinyl naphthalene, and vinyl ether, methyl vinyl ether, and acrylic acid. Other reticulators include for aldehyde and glyoxal. Preferred to be used herein as a crosslinking agent, in the methy lenbisacplamide. When the crosslinking agent is present, widely varied amounts thereof may be employed, depending on the desired properties in the final polymer, for example, effect of viscosity. Without being limited to the theory, it is believed that the incorporation of a crosslinking agent in these cationic polymers provides a material that is an agent to give more effective viscosity without negative effects, such as slip resistance and viscosity breaking in the presence of the electrolytes. The crosslinking agent, when present, may consist of about 1 ppm to about 1000 ppm, preferably about 25 ppm to about 500 ppm, more preferably about 100 ppm to about 500 ppm, and more preferably Approximately 250 ppm to approximately 500 ppm of the total weight of the polymer on a weight / weight basis. The polymerization is preferably conducted under known conditions, so that the polymers are soluble in water and have a high molecular weight, generally of 1 million, for example up to 30 million. The intrinsic viscosity of the cross-linked polymer, measured in a sodium chloride solution in a molar at 25 ° C, is generally above 6, preferably, from about 6 to about 14. These cationic polymers can be prepared by the polymerization of an aqueous solution containing from about 20% to about 60% ", generally, from about 25% to about 40% by weight of the monomer in the presence of an initiator (formally redox or thermal) until polymerization ends. When the polymer is going to be crosslinked, a suitable amount of the crosslinking agent is also added to the solution of the monomers to be polymerized to incorporate the crosslinking agent into the polymer In the polymerization reactions, the temperature at General begins low, .gr., approximately 0 ° C 95 ° C. The polymerization can be carried out by forming a reverse phase dispersion of a water phase. of the monomers (and also any of the crosslinking agents) in a non-aqueous liquid, for example mineral oil, and the like. All percentages describing the polymer in this section of the description herein are molars, unless otherwise specified. When the polymer contains acplamide, the molar ratio of the acrylamide, based on the total molar amount of acplamide, dialkylalkyl acrylate and methallylated dialkyl dialkali is generally from about 20% to about 99%, most preferably from approximately 50% to approximately 9U%. When the monomer A is present, the ratio of the monomer (A) to the monomer (B) used in this process, and thus the ratio of the groups A and B in the final polymer, on a molar basis is preferably about 99: 5 to about 15:65, more preferably from about 60:20 to about 20: 60. Alternatively, in another class of procedures, the ratio is about 5:95 to 50:50, ie, the monomer Cationic is mainly metacrical. In these procedures, the ratio is generally achieved on the scale of approximately 5:95 to approximately 25:75. In another alternative class of procedures, the ratio (A) :( B) is from about 50:50 to about 65:15, the cationic monomers being mainly acplato. Preferably the ratio (A) :( B) is from about 60:40 to about 65:15, most preferably from about 75:25 to about 65:15. It is most preferred when monomer (A) is not present and the ratio of monomer (B): monomer (C) is from about 30:70 to about 70:30, preferably from about 40:60 to about 60. : 40 and more preferably approximately 45:55 to about 55:45. A class of cationic polymers which are useful herein are especially preferred, are those which form the general structure (A) L (B), "(C) r, wherein 1 is zero, (B) is meta-plate of di-ethylamino quaternized, the ratio of (B) :( C) is approximately 45:55 to about 55:45, and the optional cross-linking agent is methylenbisacplamide. An example of such a cationic polymer is one that is commercially available as a dispersion in mineral oil (which may also include auxiliary dispersion spans, such as PPS-1 tpdecet-6) under the trade name Bal are "SC92 from Allied Colloids Ltd. (Norfoll ', Virginia) This polymer has the proposed CTFA designation "Polyquaternium 32 (and) Mineral Oil." Another class of cationic polymers useful herein are those that do not contain acrylamide monomer, ie, n is In these polymers, the monomeric components (A) and (B) are as described above.A particularly preferred group of these polymers that do not contain acplamide is one in which 1 is also zero. The polymer is essentially a homopolymer of a dialkylammoalkyl meta-platelet monomer or its quaternary ammonium salt or acid addition salt These dialkylammoalkyl metacrate polymers preferably contain a crosslinking agent as described in the above. A cationic polymer useful herein is one conforming to the general structure (A) L (B) m (C) r) wherein 1 is zero, (B) is dimethyl amine meta-platelet quaternized with methyl, n is zero , and the metilbisacplated crosslinking agent. An example of such homopolymer is commercially available as a mixture containing about 50% of the polymer, about 4% mineral oil and about 6% of PPG-1 tr? Decet-6 as a dispersion aid, from Allied Colloids Ltd, (Narfol.-, VA) under the trade name Saleare "SC95.This polymer has recently been given the CTFA designation of" Polyquaternium 37 (y) Mineral Oil (y) PPG-1 Tr? Decet-6".
ALKYL HYDROXYL ALCOHOL E CELLULQSA
The term "alkylhydroxyalkyl cellulose ethers" as used herein means polymer containing a cellulose backbone, ie, a polysaccharide skeleton of periodic glucose units. In these polymers, the hydroxy groups of the cellulose polymer are hydroxyalkylated (preferably hydroxyethylated or hydroxypropylated) to form hydroxyalkylated cellulose which is then modified with a straight chain or branched chain alkyl group of C 10 -C 30 via a linkage. ether. Typically, these polymers are ethers of straight or branched chain alcohols of C 10 -C 30 with hydroxyalkyl celluloses. Examples of alkyl groups useful herein include those selected from the group consisting of stearate, isostearyl, lauplo groups. ipstyl, cetyl, isocetyl, cocoyl (i.e., alkyl groups derived from coconut oil alcohols) palmityl, oleyl, linoleoyl, lmolenyl, phenyloyl, behenyl, and mixtures thereof. Among the preferred alkylalhydroxyalkyl cellulose ethers is the material that is given the CTFA designation of cet i lhydroxyethyl cellulose, which is the ether of the cetyl alcohol and the hydroxyethyl cellulose. This material is sold under the trade name Natrosol CS Plus of the Aqualon Corporation.
POLYMERS OF QUATERNARY AMMONIUM HYDROXYCHLORCELULOSE
By the term "quaternary ammonium hydroxyalkyl cellulose polymer" as used herein, we mean polymers that contain a cellulose backbone, ie, a backbone of polysaccharides of periodic glucose units. In these polymers, the hydro groups i of the cellulose polymer are hydroxyalkyl (preferably hydroxyethylated or hydroxypropylated) to form a hydroxyalkylated cellulose, which is further modified with a cationic or protonated quaternary ammonium group. Preferred cationic modification groups are those having at least one C10-20 alkyl chain and two shorter alkyl chains (ie, Cl or C2) in the nitrogen. The substituent on the cellulose polymer can thus be represented as - (X) NRR'R "wherein X is hyoxyalkyl <preferably - OCHBCHa.- or -0CH; i¡CHOHCH; B-), R and R 'are methyl or ethyl, and R "is C10-20 alkyl C, preferably lauplo, esteaplo, or cocoyl (ie, a mixture of alkyl groups derived from coconut oil)]. Alternatively it has been found that when R, R 'and R "are all methyl (ie, the tpmonium group) that useful cellulose polymers are also obtained.In other alternative structures, the substituent on the cellulose polymer can be presented. as - (O-OCI-.saCHa.-NRR 'R "wherein X is hydroxyalkyl (preferably -OCHaCHSA- or -OCHaCHOCH» -), R and R' are methyl or ethyl, and R "is C10 alkyl -20 C preferably lauryl, stearyl, or cocoyl (ie a mixture of alkyl groups derived from coconut oil)] Alternatively it has been found that when R, R 'and R "are all methyl (ie the tri onium group) Useful cellulose polymers are also obtained In still other alternative structures the cationic substituent in the cellulose contains both of the hydroxyethyl and hydroxypropyl groups, such that the portion can be represented as - < OCH-aCH-aO) -CHa , CH0HCH5aNRR'R ", wherein R, R 'and R" are methyl or ethyl and R "is C1 alkyl 0-20 Preferably lauryl, stearyl, or cocoyl (ie, a mixture of alkyl groups derived from coconut oil)] or alternatively wherein R, R 'and R "are all methyl (ie, the trimonium group). Commercially available cationic modified celluloses include: designated polyquaternium-24, by CTFA, which is the quaternary ammonium salt of hydroxyethylcellulose that reacts with an epoxide substituted with lauryldimethylammonium (wherein the formula - (X) ~ QCH: slCHs, -NRR'R ", X is -OCHa-CHa.-, R and R 'are methyl, and R" is stearyl). This material is sold under the trade name Quatrisoft Polymer LM-200 and is available from Amerchol Corporation.
Other commercially available cationic modified celluloses include: laurdimonium hydroxyethylcellulose (wherein in the above formula - (X) NRR'R ", X is -0CH.2CH12-, R and R 'are methyl and R" is lauplo), stearimonium hydroxyethylcellulose, in which in the formula above - (X) NRR'R ", X is, R and R 'are methyl and R" is stearate), and cocodi onium hydro? ethi -cellulose (in which in the formula above - (X) NRR'R ", X is -OCH ^ CH ^, -, R and R 'are methyl and R" is cocoyl). These three materials are known by the trade names Crodacel QL, Crodacel QS, and Crodacel QM, respectively, which are all commercially available from Croda Corp. Other cationic cellulose very useful in the hydroxypropyl cellulose (in which the group of modification in cellulose is - (OCH? aCHa.O) -CHa.CHaHCHí! NRR 'R ", in which RR' are methyl and R" is lauryl), which is available to eat only as Crodacel QL Special, of Croda Corp. Among the preferred hydroxyalkylene cellulose quaternary ammonium polymers is polyquatern? Um-23.
( / ) WATER
The emulsions of the present invention, consist of from about 25% to about 99.7%, more preferably from about 65% to about 95%, and most preferably from about 70% to about 90% of water.
OPTIONAL COMPONENTS
Each of the water and oil phases of the emulsions can consist of a wide variety of optional components. Typical of such optional components are:
FATTY ACIDS
An optional component of the present invention is a fatty acid. These fatty acids can be used to increase the viscosity of the emulsion and to provide a soft touch for the finished emulsion. When used herein, these fatty acids may consist of from about 0.1% to about 10%, more preferably from about 0.1% to about 7.5% and most preferably 0.1% to about 5% of the compositions. By the term "fatty acid" is meant any organic acid from natural or synthetic sources having from about 10 to about 40 carbon atoms, more preferably from about 10 to about 30 carbon atoms and more preferably from about 12 carbon atoms. to approximately 22 carbon atoms. The corresponding branched carbon chain materials are also included within this definition of fatty acid. Non-limiting examples of fatty alcohols include those selected from the group consisting of laupco acid, myristic acid, palmitic acid, stearic acid, isostearic acid, oleic acid, linoleic acid, linolenic acid, ricinoleic acid, behenic acid, isostearic acid and mixtures thereof. Examples of fatty alcohols are described in CTFR International Cosmetic Ingredient
Dictionarv Fourth Edition, which is incorporated herein for reference in its entirety. Also useful are the derivatives of the hydroxy substituted fatty acids described herein. Non-limiting examples of these materials include hydroxystearic acid, hydroxylalic acid, lauric hydroxy acid and mixtures thereof.
FATTY ALCOHOL
An optional component of the present invention is a fatty alcohol. These fatty alcohols can be used to increase the viscosity of the emulsion and to provide a soft touch to the finished emulsion. When used herein, these fatty alcohols may consist of from about 0.1% to about 10%, more preferably from about 0.1% to about 7.5% and most preferably from 0.1% to about 5% of the compositions. . By the term "fatty alcohol" is meant any organic alcohol from natural or synthetic sources having from about 10 to about 40 carbon atoms, more preferably from about 10 to about 30 carbon atoms and more preferably from about 12 to about 22 carbon atoms. Branched carbon chain materials are also included within this definition of fatty alcohol, correspondent. Non-limiting examples of fatty alcohols include those selected from the group consisting of lauryl alcohol, myristyl alcohol, cetyl alcohol, stearyl alcohol, isostearyl alcohol, oleyl alcohol, linoleyl alcohol, linolenic alcohol, ricinoleyl alcohol, behenyl alcohol, and mixtures thereof. Examples of fatty alcohols are described in CTFfl International Cosmetic Ingredient Dictionarv Fourth Edition, which is incorporated herein by reference in its entirety.
HUMIDANTS
Another optional component of the compositions of the present invention is a humectant. When used herein, the humectant may be from 0.1% to about 20%, more preferably from about 0.5% to about 10% and more preferably from about 1% to about 5% of the compositions. Although these materials are defined herein as humectants, they may also possess hydration, skin conditioning and other related properties. Examples of humectants useful herein include materials such as urea; guanidine; glycolic acid and glycolate salts (for example, ammonium and quaternary alkylammonium); lactic acid and lactate salts (for example, ammonium and quaternary alkylammon), zabila in any of its variety of forms (for example, zabila gel); polyhydric alcohols such as sorbitol glycerol, low molecular weight polymers (for example, dipolypropylene glycol and tripepropyl glycol), hexanotopol, propylene glycol, butyl glycol, hexyl glycol and the like; polyethylene glycol; sugars and starches; sugar derivatives < the id (eg, alkoxylated glucose); yaluronic acid; what? , starch polyacrylate grafted with starch, such as Sanwet (RTM) IM-1000, IM-1500, and IM-2500 (available from Celanese Superabsorbent Materials, Ports outh, VA); lactamide monoethanolamine; acetamide monoethanolamine; propoxylated glycerol (as described in U.S. Patent No. 4,976,953 to Orr et al., issued Dec. 11, 1990, which is incorporated herein by reference in its entirety); and its mixtures. Preferred humectants useful in the compositions of the present invention are C3-C6 urea, diols and triols, low molecular weight polypropylene glycols and propoxylated glycerin. Preferred humectants include those materials selected from the group consisting of urea, propylene glycol, 1,3-dihydroxypropane, glycerin, butylene glycol, hexymethyl glycol, 1,4-dihydroxyhexane, 1,2,6-hexanetriol, dipropylene glycol, tripropylene glycol and mixtures thereof. . Most preferred are those selected from the group consisting of urea, glycerin, butylene glycol, hexylene glycol, glycerin, dipropylene glycol, triprop and glycol and their mixtures. Most preferred are urea, glycerin and mixtures thereof.
EMOLLIENTS
The compositions of the present invention may also include an emollient. Examples of suitable emollients include, but are not limited to, volatile and non-volatile silicone oils (eg, ethylene, cycloethicon, dimethiconol, and the like), highly branched hydrocarbons and non-polar carboxylic acid and alcohol esters and mixtures thereof. The emollients useful in the present invention are further described in U.S. Patent No. 4,919,934 to Dect'ner et al., Issued April 24, 1990, which is incorporated herein by reference in its entirety. The emollients may typically consist of a total of from about 0.5% to about 50%, more preferably from about 0.5% to about 25% and more preferably from about 0.5% to about 15% by weight of the compositions of the compositions. the present invention.
ADDITIONAL INGREDIENTS
A variety of additional ingredients can be incorporated into the compositions of the present invention. Non-limiting examples of these additional ingredients include / itamines and their derivatives (eg, tocopherol, tocopherol acetate and the like); other thickening agents (for example polyacrylamide and isoparaffipa of C 3-ii + and lauret-7, available as Sepigel 305 from Seppic Corp., homopolymers of acrylic acid cross-linked with an allyl ether of pentaerythritol or an allyl ether of sucrose, which are known by the carbomer designation by CTFA and are commercially available from BF Goodrich under the trademark Carbopol; and copolymers of C10-30 alkyl acrylates with acrylic acid, alkyl esters of acrylic acid, methacrylic acid, alkyl ethers of methacrylic acid, crosslinked with an allyl ether of sucrose or an allyl ether of pentaerythritol, which are known by the designation CTFA as acrylate / acrylate crospolymers of C10-30 and are commercially available as Carbopol 1342, Pemulen TR-1, and Pemulen TR-2 from BF Goodrich); resins; gums (for example, guar gum, xanthan gum and the like); waxes (synthetic and occurring naturally); polymers to assist the film formation properties and substantivity of the composition (such as a copolymer of eicosene and vinylpyrrolidone, an example of which is available from GAF Chemical Corporation as Ganex V-220R); preservatives to maintain the antimicrobial integrity of the compositions; skin penetration aids such as DMSO, 1-dodecylazacycloheptan-2-one (available as Azone from Upjohn Co.) and the like; artificial tanning ingredients and tanning accelerators such as dihydroxyacetone, tyrosine, tyrosine esters such as ethyl thirosmate and phospho-DOPA); skin whitening agents (or brighteners) including but not limited to hydroquinone, koic acid and sodium metabisulfite; anti-oxidants; chelating agents and eliminators; and aesthetic components such as fragrances, pigments, dyes, essential oils, skin sensitizers, astringents, skin pain relieving agents, skin healing agents and the like, non-limiting examples of these aesthetic components include panthenol and derivatives (for example, ethylapantenol), zabila, pantothenic acid and its derivatives, clove oil, menthol, camphor, eucalyptus oil, eugenol, entilo lactate, amamelis distillate, allantoin, bisabalol, dipotassium glycine, and the like.
METHODS FOR SKIN CLEANSING AND DEPOSIT OF ACTIVE INGREDIENT ON THE SKIN SURFACE
The emulsion compositions of the present invention are useful for cleaning the skin and also for depositing an active ingredient on the skin during the cleaning process. Normally, an adequate amount of the cleaning composition is applied to the skin to be cleaned. It is preferred to pre-treat the skin with water. Alternatively, a suitable amount of the cleansing composition can be applied to the skin by means of the intermediate application of a cup, sponge or other application device. It has been found that the compositions of the present invention provide their optimal cleaning performance when combined with water during the cleaning process. To complete the cleaning procedure, the composition is rinsed directly from the skin with water, leaving the active ingredient on the surface of the skin. To clean the skin and deposit an active ingredient, an effective amount of the emulsion composition is used. In general, an effective amount of emulsion will depend on the needs and habits of use of the individual. The non-limiting effective amounts are in the range of about 0.5 mg / cm.sup.5 to about 5.0 mg / cm.sup.-5 of area of the skin to be cleaned.
EXAMPLES
The following examples further describe and demonstrate the embodiments within the scope of the invention. The examples are given solely for the purpose of illustration and should not be construed as limitations of the present invention, since many variations thereof are possible without departing from the spirit and scope of the invention.
The ingredients are identified by the chemical name or the CTFA name.
EXAMPLES I-Iv
CLEANING PRODUCTS CONTAINING SALICILIC ACID
A cleaning emulsion containing salicylic acid is prepared by combining the following ingredients using conventional mixing techniques.
Ingredients% Weight / Weight
II III IV
Water qs 100 os ico QS ICO QSIOO
PPG-14 Butyl Ether .0 7.0 ... 7.00
PPG-10 Butanediol 0 0 6.00?
Glycerin 3.00 3.00 3.00 3.00
Polyquaternium 37 (y) Mineral Oil (y) PPG-1 Trideceth 2. 0 2.00 1.00 0
Stearyl Alcohol 2.00 2.00 1.50 3.00
Cetyl Alcohol 2. 0 2.00 1.50 3. 0
Polyol prepolymer-25a 1.00 .50 2.00 .50
PPG-30 1.00 0.50 0 0.50
Distearil dimet i 1 ammonium chloride 0.50 .50 0.50 1.00
Cetylhydroxyethyl elulosa3 0 0 0.50 0
Urea 0.50 0.50 0 0.50
Menthol 0.20 0.20 0.20 Fragrance 0.60 0.60 0.30 0.60
Disodium EDTA 0.01 0.01 0.01 O. 1
LD? Sponble as Saleare SC95, from Allied Colloids (Suffoll ', VA). Designation proposed by CTFA for poly Cox i (methylene, 2-ethanedyl)] -alpha-hydro-omega-hydroxy-polymer with 1,1'-meth i len-b? S- ( 4-? Soc? Anatoc? Clohe-xano), which is available as Topicare 35A from Penederm Inc. (Foster City, CA) through Barnet Product Corp. (Englewood Cliffs, N3). Applicable as Natrosol CS Plus, from Aqualon Corp (Wilmington, DE). An aqueous phase is first prepared by combining the glyce- pna, disodium EDTA, hydrocarboxylic acid (if any) and water (additional water is added, later in the procedure, when 96% of the water is used appropriately), and then the mixture is heated to 75-60 ° C with stirring. In a separate container, the PPG-14 butyl ether (if any), the PPG-IO butanediol, (if any), the PPG-30 (if any) the hydroxy-terminated urethane polymer are combined with agitation to form an oil phase. Next, salicylic acid is added to this phase in oil which is heated to 75-d0 ° C with agitation. Once the salicylic acid has dissolved, cetyl alcohol, stearyl alcohol and distearyldimethylammonium chloride are added to this phase in oil with stirring. Then, this phase is added to this phase in oil with agitation, the polyquaternium 37 (and) mineral oil (and) PPG-1 tridecet (if any). Right away, the emulsion is formed by adding the oily phase to the aqueous phase with stirring using a homogenization mill. The resulting emulsion is cooled to 40 ° C while mixing. In a separate container, urea is dissolved (if any) in the remaining water and then added to the emulsion with stirring. Then the emulsion is further cooled to 30 ° C and the fragrance (if any) and menthol (if any) are added. Then the emulsion is cooled to room temperature. The resulting emulsions are useful for application to the skin for cleaning purposes. When rinsing the skin, the composition provides salicylic acid and are useful for the treatment of acne, and also for the treatment of wrinkles and other skin conditions related to age.
EXAMPLE V
CLEANING PRODUCT CONTAINING IBUPRQFEN
A cleaning emulsion containing ibuprofen is prepared by combining the following ingredients using conventional mixing techniques.
Ingredients% Weight / Weight Water QS 100
PPG-14 But i léter 6.00
Glice ina 3.00
Ibuprofen 2.00
Polyquaternium 37 (y)
Mineral Oil (y)
PPG-1 Tpdeceth 2.? O
Stearyl alcohol 2. 0
Cetyl Alcohol 2. ()
Poliolprepol number-2 1.00
PPG-30 1.00 Distearil Chloride
dimethylammonium 0.50
Urea 0.50
Menthol 0.20
Fragrance 0.60
Disodium EDTA 0.01
An emulsion is prepared using the general procedure given for Examples I-IV with 2% salicylic acid which is replaced with 2% ibuprofen. The resulting emulsion is used for application to the skin for cleaning purposes. By rinsing the skin, the composition delivers ibuprofen and is useful in providing an anti-inflammatory benefit.
EXAMPLE VI
CLEANING PRODUCT CONTAINING 2.4.4 '-TRICL0R0-2' -HIDROXIDIFENILETER
A cleaning emulsion containing 2,4,4'-trichloro-2 'hydroxydi phenyl ether (ie, triclosan) is prepared by combining the following ingredients using conventional mixing techniques.
Ingredients% Weight / Weight Water QS 100
PPG-15 Stearyl ether 6.00
Glycerin 3.00
2,4,4'-trichloro-2 '-hydro diphenyl ether 0.50
Polyquaternium 37 (y)
Mineral Oil (y)
PPG-1 Trideceth 2.00 Stearyl Alcohol 2.00
Cetyl Alcohol 2.00
Pol iolprepol number-2 1.00
PPG-30 1.00
Distearil Chloride
dimethylammonium 0.50
Urea 0.50
Menthol 0.20
Fragrance 0.60
Disodium EDTA 0.01
An emulsion is prepared using the general procedure given for Examples I-IV with 2% salicylic acid which has been replaced with 0.5% 2,4,4'-trichloro-2'-hydrodiphenyl ether. The resulting emulsion is useful for application to the skin for cleaning purposes. By rinsing the skin, the composition supplies 2,4,4'-tpchloro-2'h? Drox? D? Phenylether to the skin and is useful for treating acne and for providing an anti-microbial benefit.
EXAMPLE VII
CLEANING PRODUCT CONTAINING RETINIC ACID
A cleaning emulsion containing trans-nitric acid is prepared by combining the following ingredients, using conventional mixing techniques.
Ingredients% Weight / Weight Water QS 100
PPG-14 But i léter 6.00
Gli ce ina 3.00
Trans-ret acid 0.10
Polyquaternium 37 (y) Mineral Oil (y)
PPG-1 Trideceth 2.00
Stearyl Alcohol 1.50
Cetyl Alcohol 1.50
Pol iolprepolímero-2 1.00
PPG-30 1.00
Distearil Chloride
dimet i 1amon io 0.50
Urea 0.50
Fragrance 0.30
Disodium EDTA 0.01 An emulsion is prepared using the general procedure given for Examples I-IV with 2% salicylic acid which is replaced with 0.1% trans-60 acid.
retico inoico. The resulting composition is useful for application to the skin for cleaning purposes. By rinsing the skin, the composition provides trans-re-innocuous acid to the skin and is useful in providing treatment for acne, and also for treating wrinkles and other skin conditions related to age.
EXAMPLE VIII
CLEANING PRODUCT CONTAINING FEN0XIIS0PR0PAN0L
A cleaning emulsion containing phenoxy isopropanol prepared by combining the following ingredients is prepared using conventional mixing techniques.
Ingredients% Weight / Weight Water QS 100
PPG-14 But i léter 0.50
Glicer ina 3.00
Phenoxy isopropanol 6.00 61
Polyquaternium 37 (y) Mineral Oil (y) PPG-1 Trideceth 2.00
Stearyl Alcohol 2.00
Cetyl Alcohol 2. 0
Pol iolprepol number-2 1.00
PPG-30 1.00
Distearyl dimethyl ammonium chloride 0.50
Urea 0.50
Menthol 0.20
Fragrance 0.40
Disodium EDTA 0.01 62
An emulsion is prepared using the general procedure given for Examples I-IV with 2% salicylic acid which is replaced with 6% phenoxy isopropanol. The resulting emulsion is useful for application to the skin for cleaning purposes. By rinsing the skin, the composition delivers trans-phenoxy isopropanol to the skin and is useful in providing treatment for acne, and to provide an anti-microbial benefit.
EXAMPLE IX
CLEANING PRODUCT CONTAINING CLQTRIMAZOL
A cleaning emulsion containing clotpmazole is prepared by combining the following ingredients using conventional mixing techniques.
Ingredients% Weight / Weight Water QS 100
PPG-14 But i léter 6.00
Gli er ina 3. 0
Clortpmazol 1.00 63
Polyquaternium 37 (y)
Mineral Oil (y)
PPG-1 Trideceth 2.00
Stearyl Alcohol 1.50
Alcohol Cet Ilic 1.50
Pol iolprepol number-2 0.50
PPG-30 0.50
Distearil Chloride
dimethylammonium 0.50
Urea 0.50
Disodium EDTA 0.01
An emulsion is prepared using the general procedure given for Examples 1-IV with 2% salicylic acid which is replaced with 1% clortrimazole.
64
The resulting emulsion is useful for the application for cleaning purposes. By rinsing the skin, the composition provides clortrimazole to the skin and is useful in providing an anti-fungal benefit.
EXAMPLE X
CLEANING PRODUCT CONTAINING SUN PROTECTION
A cleaning emulsion containing sun protectants is prepared by combining the following ingredients, using conventional mixing techniques.
Ingredients% Weight / Weight Water QS 100
PPG-14 Butyl Ether 0.10
Glycerin 3.00
p-methoxynamate 2-
Etilhe ilo 7.50
Oxybenzone 3.00 65
Polyquaternium 37 (y) Mineral Oil (y) PPG-1 Trideceth 2.00
Stearyl Alcohol 2.00
Cetyl Alcohol 2. 0
Pol iolprepol number-2 1.00
PPG-30 1.00
Distearyl dimethyl ammonium chloride 0.50
Urea 0.50
Menthol 0.20
Fragrance 0. 0 66
Disodium EDTA 0.01
An emulsion is prepared using the general procedure given for Examples I-IV with 2% salicylic acid which is replaced with a mixture of 7.5% 2-ethexyl p-methoxycinnamate and 3% oxybenzone. The resulting emulsion is useful for application to the skin for cleaning purposes. By rinsing the skin, the composition delivers the 2-ethylhexyl p-methoxycinnamate and oxybenzoate to the skin and is useful in providing protection against the sun's ultraviolet rays.
Claims (16)
1. 06 skin, characterized in that the method comprises topically applying and subsequently rinsing the skin with an effective amount of a composition according to claim 1. 41. A method for cleansing the skin and depositing an active ingredient on the surface of the skin , characterized in that the method comprises topically applying and subsequently rinsing the skin with an effective amount of a composition according to claim 20. 4
2. A method for cleansing the skin and depositing an active ingredient on the surface of the skin , characterized in that the method comprises topically applying and subsequently rinsing the skin with an effective amount of a composition according to claim 29. ABSTRACT The present invention relates to oil-in-water emulsion compositions, which are useful for personal cleansing and for depositing an active ingredient on the surface of the skin. The active ingredient in compositions has a solubility parameter of about 7 to about 1
3. A preferred active ingredient is salicylic acid.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/100,957 | 1993-12-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA94005931A true MXPA94005931A (en) | 2000-07-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0714283B1 (en) | Personal cleansing compositions | |
US5989536A (en) | Personal cleansing compositions containing alkoxylated ether and cationic ammonium salt for deposition of active agent upon the skin | |
US5824666A (en) | Low PH, hydrolytically stable, cosmetic compositions containing acidic actives | |
JP3567990B2 (en) | Pharmaceutical composition for topical use containing crosslinked cationic polymer and alkoxylated ether | |
US5948416A (en) | Stable topical compositions | |
JP3471354B2 (en) | High skin penetration system for improved local delivery of drugs | |
MXPA98000188A (en) | Topic compositions es | |
EP0735866B1 (en) | Antimicrobial wipe compositions | |
KR100392676B1 (en) | Cleansing and conditioning products for skin or hair with improved deposition of conditioning ingredients | |
US8173143B2 (en) | Personal skin care compositions containing anti-flammatory and anti-microbial agents | |
DE60013098T2 (en) | COMPOSITION FOR SKIN DISINFECTION | |
JP2001522709A (en) | Wiping body article for personal cleansing with outstanding softness | |
JPH07500113A (en) | High skin penetration system for improved local delivery of drugs | |
JPH11502872A (en) | Compositions for treating hair or skin | |
CZ19598A3 (en) | Preparations for local delivery of active components | |
WO1997023594A1 (en) | Cleansing compositions | |
US20010055599A1 (en) | Compositions containing select liquid polyol fatty acid polyesters | |
MXPA94005931A (en) | Compositions of oil emulsion in water for personal cleaning | |
MXPA96004033A (en) | Low ph, hydrolically stable cosmetic compositions containing aci assets | |
MXPA97003896A (en) | Topical compositions for care of the skin containing esters of carboxylic acid of non-oclusive liquid polyol as agents of conditioning of the p | |
WO1991004730A1 (en) | Composition and methods for the stabilization of materials dispersed onto applicators | |
MXPA99010840A (en) | Compositions containing select liquid polyol fatty acid polyesters | |
PT100964B (en) | PHARMACEUTICAL COMPOSITIONS FOR TOPIC APPLICATION OF HIGH PENETRATION THROUGH THE SKIN COMPARING CERTAIN SPECIFIC CATIONIC POLYMER |